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 ABSTRACT 
 
Plasma membrane calcium/calmodulin-dependent calcium ATPases (PMCAs) are 
high affinity calcium pumps regulating many calcium-dependent processes and 
advances in its characterisation have discovered that it may play a novel role in 
signal transduction pathways. It was the aim of this work to further characterise 
and confirm the role PMCA plays in regulating calcium/calmodulin-dependent 
signal transduction pathways.  
PMCA4 has already been shown to inhibit the NFAT family of transcription factors 
by its interaction with calcineurin A in mammalian cells when ectopically 
expressed.  This prompted the investigation into other isoforms of PMCA that may 
interact with the calcium/calmodulin-dependent calcineurin, to determine if this 
interaction was isoform-specific in a variety of cell lines. Endogenous proteins 
were isolated by immunoprecipitation with calcineurin A antibody and the presence 
of PMCA isoforms was determined by western blot using isoform-specific 
antibodies. This work has demonstrated that the PMCA and calcineurin interaction 
occurs in vitro at endogenous levels in MCF-7 human breast adenocarcinoma 
cells and endothelial cells and is isoform specific, predominantly for PMCA2. The 
characterisation of the PMCA2b-calcineurin A interactive domain was performed 
and it was demonstrated that PMCA2b significantly inhibits the NFAT/calcineurin 
pathway. These results indicate that PMCA2 is important in regulating the 
calcineurin/NFAT pathway in tissues where it is highly expressed. This work also 
demonstrates that the Flag-tagged, characterised interaction domain of PMCA2 
with calcineurin, F-PMCA(462-684) when overexpressed, can disrupt the inhibitory 
PMCA2/calcineurin interaction in endothelial cells and significantly increase 
calcineurin activity. 
The expression of PMCA in endothelial cells prompted the investigation of 
calcium/calmodulin-dependent proteins in endothelial cells as evidence for the 
important role of PMCA in regulating signal transduction pathways.  
Nitric oxide synthases have been shown to be regulated by PMCA4 in cardiac 
cells. To further characterise the regulation of NOS by PMCA, this work shows that 
there is a novel molecular interaction between endogenous eNOS and the plasma 
membrane calcium ATPase (PMCA) in HUVEC primary endothelial cells. PMCA2 
has been identified as the major isoform interacting with eNOS in endothelial cells. 
 iiThe interaction between the two proteins has been mapped to the region 735-934 
of eNOS and 462-684 of human PMCA2b. NO production was found to be 
inhibited by ectopic expression of PMCA2b in HUVEC cells. Moreover, disruption 
of the interaction between endogenous PMCA and eNOS by overexpression of 
theFlag-tagged, PMCA2b interaction domain, F-PMCA2(462-684), significantly 
increased NO levels in activated HUVEC endothelial cells. In summary, these 
results offer strong evidence for a novel functional interaction between 
endogenous PMCA and eNOS in endothelial cells, suggesting a role for 
endothelial PMCA2 as a negative modulator of eNOS activity, and, therefore, NO-
dependent signal transduction pathways.  
Overall this is a novel discovery which clearly demonstrates that PMCA is an 
important regulator of calcium/calmodulin-dependent signal transduction pathways 
in various cell types. 
 
Parts of this work have been published; ‘Holton, M., Yang, D., Wang, W., 
Mohamed, T.M., Neyses, L. and Armesilla, A. (2007) The interaction between 
endogenous calcineurin and the plasma membrane calcium-dependent ATPase is 
isoform specific in breast cancer cells. FEBS letter. 581(21), 4115-4119.’ and 
presented at ‘The 14
th congress of calcium binding proteins, La Palma, Canary 
Islands, Spain. 2007’ and ‘The 25th Conference of the European Society on 
Microcirculation (August 26-29, 2008, Budapest, Hungary).’ 
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1. CHAPTER ONE: 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 11.1   PLASMA MEMBRANE CALCIUM/CALMODULIN-DEPENDENT ATPASE 
 
The Plasma Membrane calcium/calmodulin-dependent ATPase  
(PMCA) is a P-type calcium ATPase pump (Pederson et al., 1978 and Pederson et 
al., 1987). Its main function is to export calcium, against a concentration gradient 
from the intracellular matrix to the extracellular milieu (Rosado et al., 2004). This is 
important because calcium is a regulator of gene transcription and therefore, many 
cellular processes such as, angiogenesis and cell proliferation, (Rosado et al., 
2004). There are other proteins besides PMCA that control intracellular calcium 
concentrations such as Sarco/endoplasmic reticulum Ca
2+-ATPase (SERCA) or 
Na
+/Ca
2+ pumps. PMCA has not been characterised to the same degree as other 
calcium pumps and research into this ATPase will provide a more detailed 
explanation for the role of calcium and the effects it can have on various 
processes, as well as providing another, possibly more specific, avenue for the 
manipulation of intracellular calcium levels and the cellular processes controlled by 
them. 
 
1.1.1  PMCA genomic structure 
There are four PMCA isoforms (PMCA1, 2, 3 and 4) which are the products of four 
independent genes located on chromosomes 12, 3, X and 1 respectively 
(reviewed in Strehler and Zacharias, 2001). The structure of PMCA genes have 
only been partially characterised due to their large size, which is between 70kb to 
over 100kb depending on the isoform, and information on regulatory domains is 
scarce (Burk and Schull, 1992 and Hilfiker et al., 1993). The four isoforms of 
PMCA share a high degree of sequence homology. All show the features 
described in fig. 1.1.1 and are predicted to have a very similar structure (Strehler 
and Zacharias, 2001). 
 
 
 
 
 
 
 2Research into the characterisation of the PMCA isoforms has shown that they are 
distributed differently in certain tissues. PMCA1 and 4 are ubiquitously expressed 
in most tissues, PMCA2 is expressed mainly in cerebellar Purkinje cells with some 
heightened expression in the uterus, liver, kidney and lactating mammary glands, 
thought to provide the high calcium levels found in breast milk, and PMCA3 is the 
least expressed found only in the brain and, at certain time points, in the skeletal 
muscle, (Strehler and Zacharias, 2001).  
 
1.1.2  PMCA protein structure 
The structure of PMCA consists of ten transmembrane domains with the bulk of 
the protein residing on the cytosolic side of the membrane. Domains of interest 
include the transduction domain, the ATPase domain and the C-terminal domain 
which contains a calcium/calmodulin binding domain and a PDZ-binding domain. 
PDZ binding domains bind to the carboxyl end of proteins or form dimers with 
other PDZ domain containing proteins, they are named after PSD-95, discs large, 
zona occludens 1 proteins (Kim et al., 2004). The transduction domain lies 
between transmembrane domains 2 and 3 (Fig. 1.1.1), it is important in the 
conformational change of the protein during activation and also contains an 
important domain for phospholipid activation (Niggli et al., 1981).The transduction 
domain also contains a site for alternative isoform splicing, known as splice site A. 
The ATPase domain lies between transmembrane domains 4 and 5 (Fig. 1.1.1), 
this is also known as the catalytic domain of the protein and includes an ATP 
binding site and aspartate residues which during ATP hydrolysis are important for 
the formation of an acyl phosphate intermediate. The C-terminal domain contains 
a binding site for proteins containing PDZ domains and also a site for alternative 
splicing, splice site C that overlaps the site for calcium/calmodulin binding and the 
autoinhibition domain. This domain is considered the major regulatory domain of 
PMCA (Penniston et al., 1998). See fig. 1.1.1 for a structural representation of 
PMCA. 
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Fig. 1.1.1 The structure of PMCA. (adapted from Strehler and Zacharias, 2001). All isoforms of 
PMCA contain the same important domains which are important for its function and regulation of its 
activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41.1.3  PMCA splice variants 
Over twenty splice variants of the PMCA pumps have been described (Fig. 1.1.2). 
These splicing events occur in splicing sites A and C located in the transduction 
domain and the c-terminal domains respectively (Di Leva et al., 2008).  
 
 
 
Fig. 1.1.2 The alternative splice variants for each PMCA isoform (Di Leva et al., 2008). All the 
variation of PMCA splice variants occurs at either the A-splice site within the first intracellular loop 
or the C-splice site in the C- terminal domains of the protein. 
 
Each splice variant is thought to involve the localisation and specialisation of 
PMCA to a particular cell type or function, for example splice variant PMCA2w/a is 
mostly in the stereocilia of hair cells (Hill et al., 2006). 
 
 
 
 51.1.4  Regulation of PMCA activity 
PMCA is an important regulator of intracellular calcium levels therefore, the control 
of its activity is of paramount importance and is exerted through various 
mechanisms at several levels. 
 
1.1.4a Calcium calmodulin 
PMCA is regulated by the intracellular concentrations of calcium/calmodulin. In an 
inactive state PMCA activity is suppressed by binding of an autoinhibitory domain 
(located on the C-terminus) to two regions located in the transduction and catalytic 
domains (Fig. 1.1.3). When calcium/calmodulin binds to PMCA it displaces the 
autoinhibitory domain from the active site of PMCA allowing it to pump calcium 
from the cell via the ATPase pump. It has been discovered that the binding of 
calcium/calmodulin to PMCA can occur with two different effects. 
Calcium/calmodulin can bind to PMCA without dissociating the autoinhibitory 
domain, therefore rendering the pump inactive, or can cause the displacement of 
the autoinhibitory domain and activate the pump (Osborn et al., 2004). This 
indicates that the pump exists in three different states; inactive, partially inactive 
and active depending on the local calcium concentration, it is hypothesised that 
the partially inactive state would allow rapid response to changes in intracellular 
calcium concentrations (Osborn et al., 2004). 
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Fig. 1.1.3 Regulation of PMCA by calcium/calmodulin adapted from Osborn et al., 2004. PMCA 
exists in 3 regulatory conformations. A) Conformation 1 represents the inactive form of PMCA 
where the autoinhibitory domain blocks PMCA activity. B) Conformation 2 represents the partially 
active form where calcium/calmodulin is bound to PMCA but the autoinhibitory domain is also still 
bound. C) Conformation 3 represents the active form where calcium/calmodulin is bound and 
displaces the autoinhibitory domain resulting in PMCA activation. 
 
1.1.4b Transcriptional control 
The transcriptional control of PMCA has not been studied extensively; however, a 
few groups have reported that the expression of PMCA isoforms is regulated by 
different mechanisms. Ximenes et al. (2003) have demonstrated that in pancreatic 
islet cells the transcription and expression of all PMCA isoforms, in particular 
PMCA2, is decreased by high glucose levels. The reason is thought to be the cells 
switching from a low efficiency calcium pump to a higher efficiency pump, as 
calcium plays an important role in insulin release.  
In neurons it is thought that PMCA4 expression is controlled directly by calcineurin 
or indirectly through NFAT-mediated pathways as they found that fully active 
calcineurin reduced the expression of PMCA4 during the neuron maturation 
process, no effect was observed on the expression of the other PMCA isoforms 
(Guerini et al., 2000).  
 7Caride et al. (1999) have shown that by decreasing the level of protein in diet and 
decreasing calcium reabsorption the transcription of PMCA2 and 3 was markedly 
decreased in kidney parenchyma cells, whereas, the transcription of PMCA1 and 4 
remained the same. The effect is thought to be mediated by calcium levels 
resulting in reduced calcium reabsorption and excretion in the kidney tubules.  
Similarly Guerini et al. (2000) have shown that in cerebellar granule neurons the 
transcription of PMCA genes isoforms was dependent on sustained intracellular 
calcium increases, however the stability of the mRNA and its translation efficiency 
may also be upregulated by calcium.  
Pannabecker et al. (1995) also describe another mechanism for PMCA1 and 4 
transcriptional regulation in the intestine by vitamin D3 (1,25-dihydroxyvitamin D3 
[1,25(OH)2D3]). Vitamin D3 is thought to exert its effects by the presence of a 
vitamin D3 regulatory response element in the PMCA promoter, however, this has 
not been fully characterised (Lowe et al., 1992).  
PMCA expression is controlled in a tissue-specific manner in muscle during 
myogenic differentiation, Hammes et al. (1994) have shown that a myogenic 
determination factor can result in the expression of different PMCA isoforms and 
splice variants and it is thought to exert its effects on the PMCA promoter at it’s 
specific DNA motif. Overall it seems the transcriptional control of PMCA is 
essential for the tissue, isoform-specific expression of PMCA. 
 
1.1.4c Post-translational modifications 
1.1.4c(i) Phosphorylation 
PMCA is phosphorylated by protein kinases, such as PKC, PKA, Src kinase and 
focal adhesion kinase (FAK) (reviewed in Di Leva et al., 2008). The sites for these 
phosphorylations are either serine/threonine or tyrosine residues (Di Leva et al., 
2008). Phosphorylation of tyrosine residues of PMCA results in a significant 
reduction of PMCA activity, it is hypothesised that this inhibition is important in 
platelet activation (Dean et al., 1997). 
 
 
 
 
 
 81.1.4c(ii) Acidic  Phospholipids 
Phospholipids are the main component of cell membranes, many different types of 
phospholipid exist and the ratio of acidic phospholipids within the membrane has 
been found to regulate PMCA (Tang et al., 2006) by increasing the affinity of 
PMCA for calcium (Niggli et al., 1981). One of the most interesting phospholipids 
with respect to PMCA activation is phosphatidylinositol bisphosphate (PIP2), 
because its composition in the plasma membrane is greatly affected by external 
stimuli (Di Leva et al., 2008).  
 
1.1.4c(iii) Lipid  rafts 
Lipid rafts are specialised domains of the plasma membrane high in cholesterol 
and glycosphingolipids, which are important in signal transduction (Sepulveda et 
al., 2005). PMCA4 has been found in high concentrations at lipid rafts suggesting 
it has an important role in cell signalling, especially in cerebellum synapses, 
(Sepulveda et al., 2005). Tang et al. (2006) have shown that PMCA4 activity 
depends on the lipid composition and structure of the membrane, this changes 
with age and disease and may affect PMCA activity leading to calcium imbalance 
within cells. 
 
1.1.4c(iv) Proteolytic  cleavage 
PMCA has been shown to be digested by calpain and caspases. Calpain cleaves 
PMCA at a site upstream from the calmodulin binding domain resulting in an 
irreversible constitutively active form of the pump (James et al., 1989). The activity 
of caspases on PMCA activity has been investigated in more detail than calpains. 
Caspase-3 and to a lesser extent Caspase-7 has been shown to cleave PMCA in 
apoptotic cells resulting in irreversible activation of the pump and alteration of 
intracellular calcium concentrations, known to be important in apoptosis (Paszty et 
al., 2002). Paszty et al. (2005) have also shown that PMCA4 is targeted to the 
plasma membrane and is fully active without the need for calmodulin during 
apoptosis. However, Schwab et al. (2002) have evidence that cleavage by 
caspases can result in complete inactivation of PMCA possibly due to the further 
degradation of the pump during the apoptotic process leading to secondary 
necrosis. 
 
 91.1.5 Knockout  models 
Knockout models are often used to determine any biological process in which the 
expression of a protein is essential, they usually involve the production of a mutant 
mouse that is lacking the gene for a certain protein or a mouse that has been 
genetically engineered not to express a certain protein. PMCA knockout mice for 
PMCA isoforms are described here. 
 
1.1.5a PMCA1 
Attempts to produce knockout systems for PMCA1 have failed as it results in 
embryonic lethality (Prasad et al., 2004), indicating its importance in 
embryogenesis. One study by Okunade et al. (2004) has demonstrated that 
PMCA4 knockout mice that are also heterozygous for PMCA1 have increased 
VSMC apoptosis. This heterozygous mouse model also indicates that PMCA1 is 
important in the removal of calcium from bladder smooth muscle (Liu et al., 2006).  
 
1.1.5b PMCA2 
PMCA2 knockout studies have shown that lack of PMCA2 results in problems with 
hearing and balance, producing a mouse model known as deafwaddler. The 
balance phenotypic characteristics of the knockout mouse were thought to be a 
result of high calcium levels in cerebellar purkinje cells, however, although 
changes are seen in the number of purkinje cells, they were deemed not 
significant enough to produce the severe balance defects (Kozel et al., 1998). The 
current theory is that PMCA2 is essential for the formation of otoconia, calcium 
carbonate crystals found in the inner ear involved in sensing acceleration and 
gravity, important in balance (Kozel et al., 1998).  
Mice homozygous for a null-mutation of the PMCA2 gene produced milk with 60% 
less calcium than wild type animals suggesting an important role for PMCA2 in 
macrocalcium secretion (Reinhardt et al., 2004). Kurnellas et al. (2005) have 
demonstrated that PMCA2 may be important in the clearance of calcium from 
spinal cord motor neurons and PMCA2 null mice display neuronal cell damage. 
 
1.1.5c PMCA3 
A PMCA3 knockout mouse has not been reported (Prasad et al., 2007).  
 
 101.1.5d PMCA4 
PMCA4 knockout studies show that lack of PMCA4 causes low sperm motility due 
to its necessary presence in the flagellar apparatus of the sperm tail, (Schuh, et 
al., 2004). Liu et al. (2005) have also shown that PMCA4 is involved in the 
contractility of bladder smooth muscle, where PMCA4 accounts for 25-30% of the 
muscles relaxation. PMCA4 has also been implicated in the negative regulation of 
B lymphocytes by interacting with CD22, a transmembrane glycoprotein found only 
in B cells, and increasing calcium expulsion after B cell receptor activation (Chen 
et al., 2004).  
 
1.1.6  PMCA in physiological processes 
The importance of PMCA in controlling calcium levels within cells means that it 
plays a significant role in many physiological processes that use calcium as a 
signalling mediator. In vivo and  In vitro studies have shown the relevance of 
PMCA function in several physiological processes described here. 
 
1.1.6a Apoptosis 
Apoptosis or programmed cell death occurs either by the activation of death 
receptors or by limited growth/survival factors due to stress (Peluso et al., 2003). 
Apoptosis due to stress usually involves an increase in intracellular calcium 
concentration (Yu et al., 2001). Schwab et al. (2002) have shown that PMCA2 and 
4 are cleaved by caspases at a site close to the C-terminal end of PMCA during 
neuronal cells apoptosis resulting in a lack of PMCA function, degradation and a 
subsequent increase in intracellular calcium levels. This hypothesis is further 
confirmed in work by Chami et al. (2003) that demonstrated that PMCA is 
inactivated by caspase-3 cleavage. 
 
1.1.6b Tumour Necrosis Factor (TNFα)-induced cell death 
TNFα is a proinflammatory signalling molecule and has been shown to induce cell 
death in certain cell types by apoptosis or necrosis (Beyaert et al., 1994). Ono et 
al. (2001) have demonstrated that when PMCA4 was mutated in murine 
fibrosarcoma cells they became resistant to TNFα-induced cell death. This was 
discovered to be due to an elevation in intracellular calcium and the subsequent 
effect on lysosome function and their inability to increase in volume. 
 111.1.6c Neuronal development 
Neuronal cell differentiation is known to be controlled by calcium concentrations. 
Usachev et al. (2001) have shown that calcium efflux by PMCA increased 
significantly during neuronal cell differentiation and that the PMCA2, 3 and 4 
isoforms were upregulated. Conversely Brandt et al. (1996) demonstrated, using a 
derivative of the same cell line, that PMCA1 was important in neurite extension. 
Schwab et al. (2002) have shown that PMCA2 is important in the apoptosis and 
secondary necrosis of neuronal cells after ischemia. PMCA2 has also been 
demonstrated to be highly important in purkinje neurons where it is involved in 
signalling for motor coordination, synaptic plasticity, synapse elimination and 
learning (Kurnellas et al., 2007). These investigations suggest that different 
isoforms of PMCA may be important at different stages of neuronal cell 
development.  
 
1.1.6d Platelet aggregation 
Platelets are activated by increases in cytosolic calcium (Sargeant et al., 1994). It 
is hypothesised that PMCA is an important regulator of platelet activation. It has 
been observed that PMCA is often overexpressed in platelets of diseased 
individuals such as diabetics and hypertensives as described below. Inhibition of 
PMCA activity by tyrosine phosphorylation has been shown to be important during 
thrombin-mediated activation of platelets suggesting an essential role for the 
inhibition of PMCA in rapid platelet aggregation (Bozulic et al., 2007). 
 
1.1.6e Calcium influx into milk 
The mammary gland requires high levels of calcium from the blood for inclusion in 
the production of milk (Reinhardt et al., 1998). This influx of calcium into mammary 
secretory cells is tightly controlled. The expression of PMCA2 has been shown to 
be upregulated during lactation and its expression is clearly important in the 
production of milk calcium and milk proteins in mammary gland milk production 
(Reinhardt et al., 2004). 
 
 
 
 
 121.1.6f Kidney reabsorption of calcium 
In the kidney, the renal tubules are important in the reabsorption of calcium. 
Blankenship et al. (2001) demonstrate that the regulation of this reabsorption 
depends on the inhibition of PMCA. Magyar et al. (2002) have shown that the 
predominant isoforms of PMCA expressed in the renal tubules are 1 and 4. The 
regulation of PMCA expression and membrane localisation in the distal kidney is 
affected by hormones, in particular vitamin D3 (Kip et al., 2004) and oestrogen (Oz 
et al., 2007). 
 
1.1.6g Sperm motility 
Sperm motility is essential for the successful fertilisation of the female egg. Schuh 
et al. (2004) have demonstrated that PMCA4 is highly expressed in the testis and 
localised to the flagellar of the sperm tail, implying its importance in sperm motility. 
By knocking down the expression of PMCA4 sperm motility was inhibited, however 
the sperm still had the capacity for fertilisation (Okunade et al., 2004). 
 
1.1.7  PMCA in diseases 
As well as having a significant role in certain physiological processes PMCA has 
also been shown to be important in many pathological conditions either through 
aberrant expression or activity. 
 
1.1.7a Cancer 
Cancer is the unregulated growth of cells resulting in the formation of detrimental 
tumours. An imbalance in calcium levels has been shown to contribute to cellular 
proliferation and tumorigenesis (Hanahan and Wein, 2000). Lee at al. (2002) 
suggest that calcium transport proteins may play an important role in regulating 
calcium levels. The expression of PMCA in breast cancer cells has been 
demonstrated to be upregulated compared to non-tumorigenic breast epithelial 
cells supporting this hypothesis (Lee et al., 2005). Delgado-Coello et al. (2003) 
have shown that this is also the case in murine hepatocarcinomas compared to 
normal or regenerating liver, higher levels of ATPase protein were found in 
cancerous liver cells. Aung et al. (2007) have demonstrated that during colon 
cancer cell differentiation the levels of PMCA 4 mRNA are upregulated however 
the functionality of this upregulation has yet to be determined. Ribiczey et al. 
 13(2007) have also shown that PMCA expression is aberrant in colon and gastric 
cancer cells. In Human oral cancer cells Saito et al. (2006) hypothesise that the 
PMCA1 gene may function as a tumour suppressor as a lack of PMCA1 
expression is associated with oral cancer progression. PMCA1 has been found to 
be underexpressed in oral cancer cells caused by inhibition of its 
transcription/translation by DNA methylation (Saito et al., 2006). Clearly the PMCA 
isoform and its expression are different depending on the cancer cell type. 
 
1.1.7b Heart disease 
Hypertension means an increase in blood pressure. Zwadlo et al. (2005) have 
observed that the expression of PMCA2 is significantly increased in hypertensive 
individuals and is possibly involved in regulating myocardial growth (Hammes et 
al., 1998). However Blankenship et al. (2000) have also demonstrated that PMCA 
is often tyrosine phosphorylated in platelets from hypertensive individuals reducing 
the activity of the pump and therefore increasing the levels of cytosolic calcium 
enhancing platelet activation and increasing the risk of thrombosis.  PMCA has 
also been implicated in myocardial infarction, where Mackiewicz et al. (2008) have 
shown that PMCA activity decreases during the three months after an attack and 
this decrease may cause myocyte shortening. 
 
1.1.7c Hearing loss 
Calcium regulates mechanoelectrical transduction in the inner ear, therefore the 
expression of PMCA is important in modulating calcium levels (Brini et al., 2007).  
Furuta et al. (1998) demonstrated that the predominant isoform of PMCA in the 
inner and outer hair cells of the auditory systems is PMCA2. Kozel et al. (1998) 
characterised the PMCA2 knockout mouse to suffer from hearing loss due to the 
normally high expression of PMCA2 in the hair bundle, and Konrad-Martin et al. 
(2001) suggest that PMCA2 is essential for high frequency hearing. Also noted by 
Penheiter et al. (2001) was the fact that a lack of PMCA2 was not compensated by 
overexpression of any of the other PMCA isoforms. 
 
 
 
 
 141.1.7d Diabetes 
Diabetes is a disease caused by a defect in the synthesis, secretion or function of 
insulin. β-cells express all 4 isoforms of PMCA and the effect of increased glucose 
on PMCA in β−cells is to switch from PMCA to a high capacity calcium pump to 
counteract the inflow of calcium (Herchuelz et al., 2007). The platelets of diabetic 
patients often have deregulated PMCA expression. Rosado et al. (2004) have 
demonstrated that PMCA tyrosine phosphorylation is higher is platelets from 
diabetic patients than from normal patients resulting in decreased calcium 
extrusion which may increase platelet aggregation and thrombosis formation. 
Chaabane et al. (2007) demonstrate that the isoform expressed most in diabetic 
patient platelets is PMCA4 and that the high expression of this PMCA during 
platelet development may lead to megakaryocytopoiesis or enlarged platelets 
leading to abnormal platelet function in diabetic patients leading to the 
cardiovascular disease often associated with diabetes. 
 
1.1.7e Multiple sclerosis (MS) 
MS is a chronic inflammatory disease resulting in demyelination, axonal and 
neuronal cell death (Hafler 2004). Kurnellas et al. (2007) summarise that PMCA2 
is important in the balance of calcium in axonal and neuronal cells and that 
inhibition of PMCA2 results in cytoskeletal changes, neurite swelling and neuronal 
death. In fact they report that PMCA2 levels decline in MS models (Kurnellas et 
al., 2005). 
 
1.1.7f Cataracts 
Cataracts are thought to be caused mostly by an increase in intracellular calcium 
in the human lens resulting in increased opacity or lack of transparency, as 
calcium levels in cataractous lenses are often elevated by 3-3000 fold that of non-
cataractous lenses (Marian et al., 2007). In human lens epithelial cells it has been 
shown that PMCA1 expression is upregulated in the presence of high intracellular 
calcium levels, suggesting that in some patients with cataracts a lack of functional 
PMCA1 may allow for the build up of intracellular calcium and increased opacity 
(Marian et al., 2007). 
 
 151.1.8 PMCA as a regulator of signal transduction pathways: Protein 
partners 
PMCA participates in the regulation of physiological and pathological processes 
via its interaction with partner proteins that play essential roles in signal 
transduction pathways implicated in the control of these processes. PMCA 
interacts with many proteins at various regions, some of these regions are specific 
and can be predicted, such as PDZ-domains present in the interaction partner 
proteins, other interactions are more difficult to predict. Below is a review of the 
current known partner proteins of PMCA.  
 
1.1.8a C-terminal interactions 
The C-terminal domain of PMCA contains a PDZ-binding domain which is 
important for interactions with proteins containing this domain, these are described 
below. 
 
1.1.8a(i)  Membrane Associated Guanylate Kinases (MAGUK)  
MAGUK are a family of multimodular proteins involved in the formation of cell-cell 
junctions and cellular signalling. A subfamily of MAGUK is the synapse-activated 
proteins (SAPs) which are thought to be scaffolding proteins (DeMarco and 
Strehler, 2001). Both PMCA isoforms 2 and 4 have been found to interact with 
MAGUK family members via their PDZ domain. Their interaction with PMCA2 and 
4 is thought to be involved in localising multiprotein complexes to the plasma 
membrane, any functionality of the interaction has yet to be determined (Kim et al., 
1998). 
  
1.1.8a(ii)  Ania 3/Homer protein  
Ania 3/homer proteins are involved in the localisation of metaboltropic 
glutamatergic receptors with other channels and receptors in the brain and are 
thought to link extracellular signals with Ca
2+ release and mediate PDZ protein 
interactions (Sgambato-Faure 2006). The Ania 3/Homer protein interacts with 
PMCA4 via its PDZ domain and inhibits the activity of PMCA4 (Rimessi et al., 
2005) 
                                        
 
 161.1.8a(iii) Na
+/H
+ Exchanger Regulatory Factor 2 (NHERF2) 
NHERF2 are responsible for the removal of Ca
2+ from cells (DeMarco 2002). They 
have been reported to interact with many receptors and membrane transporters 
and are thought to be scaffolding proteins for the localisation of signalling 
molecules and transmembrane proteins (Bretscher 1999). The interaction has yet 
to be functionally characterised but only PMCA2 has been shown to be involved in 
the interaction with NHERF2 via its PDZ domain (DeMarco 2002). 
 
1.1.8a(iv)  Neuronal nitric oxide synthase (nNOS)  
nNOS is responsible for producing NO in neuronal and cardiac cells. It contains a 
PDZ domain and is part of a large multi-protein complex. PMCA4 has been shown 
to interact with nNOS via its PDZ domain and inhibit its activity, this is thought to 
occur by the tethering of the protein to a low calcium microenvironment (Schuh et 
al., 2001). Oceandy et al. (2007) have shown that the interaction between PMCA4 
and nNOS is functional in vivo where it regulates cardiac contractility.  
 
1.1.8a(v) PMCA-interacting single-PDZ domain protein (PISP) 
PISP is ubiquitously expressed in all tissues and interacts with all b-splice variant 
isoforms of PMCA. It is small in size and contains only one PDZ-domain making it 
unlikely to be involved in localising proteins. It is thought to function solely as a 
chaperone protein for b splice variants of PMCA in processes such as signalling, 
endocytosis and trafficking. (Goellner et al., 2003). 
 
1.1.8a(vi) CLP36 
CLP36 is a PDZ domain containing enzyme that also contains a LIM domain 
important in protein associations with the cytoskeleton (Sadler et al., 1992) CLP36 
interacts with PMCA4 and also α-actinin-1 and actin tethering the pump to the 
cytoskeleton in platelets, possibly regulating the pumps activity in these cells 
(Bozulic et al., 2007). 
 
 
 
 
 171.1.8a(vii) CD22 
CD22 is a transmembrane glycoprotein found only in B cells. Upon B cell receptor 
stimulation intracellular calcium concentrations increase resulting in the activation 
of B cell proliferation, differentiation and CD22 phosphorylation. PMCA4 seems to 
interact with phosphorylated CD22 where it is activated and increases calcium 
efflux (Chen et al., 2004). The site or mechanism of interaction has not been 
defined.  
 
1.1.8b Large intracellular loop interactions 
The large intracellular loop of PMCA lies between transmembrane domains 4 and 
5, this is the site of the pump’s ATPase activity and the point where hypothetically 
calcium-dependent proteins are inhibited by the low calcium microdomain created 
by PMCA’s calcium extrusion activity. 
 
1.1.8b(i) Rassf1 
Armesilla et al., (2004) have shown that PMCA4 interacts with the tumour 
suppressor protein RASSF1. The interaction between PMCA4 and RASSF1 
significantly inhibited EGF-dependent activation of the ERK pathway in HEK293 
mammalian cells. 
 
1.1.8b(ii)  α−1 Syntrophin 
Syntrophins interact with proteins involved in organising signal transduction 
pathways and are part of a dystrophin complex involved in important physiological 
processes (Suzuki et al., 1995). Williams et al. (2006) have demonstrated that 
PMCA1 and 4 interact with α-1 syntrophin in cardiac cells at a domain different to 
its PDZ domain, suggesting that PMCA, nNOS and α-1 syntrophin exist as a 
macromolecular protein complex.  
 
 
 
 
 
 
 181.1.8b(iii) Calcineurin  (PP2B) 
Calcineurin is a calcium-dependent serine/threonine protein phosphatase 
(Namgaladze et al., 2005). Buch et al. (2005) have demonstrated that PMCA4 
interacts with calcineurin at a site located within the large intracellular loop 
between transmembrane domains 4 and 5 and inhibits calcineurin activity. It is 
hypothesised that PMCA4 tethers calcineurin to a low calcium micoenvironment 
created by the pump calcium extrusion capabilities and therefore inhibits its activity 
(Buch et al., 2005). 
 
1.1.8c N-terminal interactions 
The N-terminal domain of PMCA has not been identified to interact with many 
proteins, however, one has recently been discovered and is described below. 
 
1.1.8c(i) 14-3-3ε  
The 14-3-3 protein family are small acidic proteins thought to be involved in 
altering protein conformation to enhance phosphorylation events (Mackintosh 
2004). Rimessi et al. (2005) have shown that 14-3-3 proteins interact with PMCA4 
at a site within PMCA4 N-terminus resulting in inhibition of PMCA4 activity. This 
interaction is unusual as 14-3-3 proteins routinely interact at phosphoserine or 
phosphothreonine sites within proteins, of which the N-terminal domain of PMCA4 
does not contain (Rimessi et al., 2005). 
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Fig. 1.1.4 PMCA interaction partners. (adapted from Di Leva et al., 2008). PMCA partner proteins 
all bind to the intracellular portion of the PMCA molecule. Their varying effects on PMCA allow for 
its regulation and in turn activity of the partner protein is often governed by PMCA.  
 
1.1.9 Summary 
Emerging evidence suggests a novel role for PMCAs as regulators of signal 
transduction pathways. This new function involves the interaction of PMCA with 
calcium-dependent proteins and tethering them to low calcium microdomains 
created by the pump’s calcium extrusion function. The aim of this project was to 
demonstrate the importance of PMCA in regulating calcium-dependent signal 
transduction and to evaluate the role of different PMCA isoforms in the 
interaction/regulation of calcineurin. Moreover, the previous demonstration of 
PMCA as a regulator of NO production via interaction with nNOS in neuronal cells 
prompted us to investigate the possibility of a molecular interaction between 
PMCA and eNOS; the major NO synthase expressed in endothelial cells. For this 
reason the calcineurin and nitric oxide synthase signalling pathways will be 
described in more depth later in this introduction. 
 
 
 
 
 201.2  THE CALCINEURIN/NFAT SIGNAL TRANSDUCTION PATHWAY 
 
Calcineurin, also known as, protein phosphatase 2B, is a member of the 
serine/threonine phosphatases protein family (Namgaladze et al., 2005). This 
family of phosphatases also includes protein phosphatases 1 (PP1), 2A (PP2A) 
and 2C (PP2C) all of which have been found to be important for signal 
transduction pathways (Shenolikar and Nairn, 1991). Calcineurin is ubiquitously 
expressed in eukaryotic cells and is involved in the regulation of apoptosis (Wang 
et al., 1999), angiogenesis (Hernandez et al., 2001), immune response (Winslow 
et al., 2003) and other biological processes (reviewed in Crabtree and Olson. 
2002). 
 
1.2.1  Calcineurin genomic structure 
The protein itself is made up of two subunits; one catalytic (subunit A) and one 
regulatory (subunit B) encoded by separate genes. Calcineurin A exists as three 
isoforms in humans; α, β and γ that are produced by 3 separate genes located on 
chromosomes 4, 10 and 8 respectively (Giri et al., 1991). Calcineurin B exists in 
two variants generated from one gene found on chromosome 2, one variant is 
ubiquitously expressed and the other seems to be expressed in the testes only 
(Chang et al., 1994). 
 
1.2.2  Calcineurin protein structure 
Calcineurin A includes four functional domains (Fig. 1.2.1); an autoinhibitory 
domain, a catalytic domain, a calmodulin binding domain and a binding site for the 
regulatory subunit calcineurin B (Qin et al., 2003). These functional domains are 
conserved among species, however, the COOH and NH2 termini vary greatly 
between species as do the calcineurin A genes (Kincaid 1993). Calcineurin is self-
regulated by the presence of an autoinhibitory domain which allows binding of the 
regulatory subunit B. Calcineurin B is displaced upon activation by 
calcium/calmodulin leading to functional calcineurin (Klee et al., 1998). The affinity 
of calcineurin B for calcineurin A is so high that only strong denaturation can 
disassociate the two proteins (Merat et al., 1987).  
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The active site of calcineurin, responsible for protein dephosphorylation, contains 
iron and zinc ions at a binuclear centre. This iron molecule can be subjected to 
oxidisation by superoxides resulting in a marked reduction in calcineurin activity 
(Namgaladze et al., 2002). 
 
1.2.3 Calcineurin-dependent activation of Nuclear Factor of Activated T-
cells, (NFATs) 
NFATs are one of the main substrates for calcineurin. NFAT are a family of 
transcription factors including five members; NFAT1, 2, 3, 4 and 5 (Rao et al, 
1997). The NFAT proteins consist of an N-terminal transactivation domain, 
followed by a regulatory domain, a conserved DNA binding domain and a C-
terminal domain (Fig. 1.2.2)  
 
Fig. 1.2.1  Calcineurin protein structure, (adapted from Schulz and Yutzey, 2004). Calcineurin 
is divided into two definable protein subunits; calcineurin A and calcineurin B. A contains 
catalytic and regulatory domains which interact with calcineurin B (CNB) calmodulin (CaM) and 
allow for autoinhibition (AI). B contains sites for calcium binding, (C) which ultimately regulates 
the activity of calcieurin. 
calcineurin subunit A 
   
C C C C
calcineurin subunit B 
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Fig. 1.2.2  NFAT isoforms and domain structure. (Adapted from Macian et al., 2001 and Martinez-
Martinez et al., 2006). The regulatory domain has been enlarged to demonstrate important motifs 
involved in activating NFAT and regulating its activity. The regulatory domain contains two serine-
rich regions (SRR-1 and SRR-2), three serine-proline rich regions (SP-1, -2 and -3), a calcineurin 
docking domain (PxIxIT) and a nuclear localisation domain (NLS). Conserved phosphoserines that 
become dephosphorylated upon activation are shown as purple circles. The inducible 
phosphorylation site is shown as a blue circle.  
 
NFAT5 is not activated by calcineurin but shares a high degree of homology with 
the DNA binding domain of the other NFAT family members (Pan et al., 2000). 
During the remainder of this thesis when NFAT is mentioned it will refer to NFAT1-
4 unless specifically stated. NFAT are activated by a sustained increase in 
intracellular calcium leading to calcineurin activation. The binding of calcineurin to 
NFAT involves a conserved sequence motif, PxIxIT, located in the regulatory 
domain of NFAT (Amburu et al., 1998). Calcineurin dephosphorylates NFAT at 
multiple serine residues found in the NFAT regulatory domain causing the 
exposure of the nuclear localisation sequences (NLS) (Im et al., 2004). Upon 
complete dephosphorylation by calcineurin, a nuclear export sequence (NES) is 
hidden resulting in the nuclear translocation of NFAT. Once in the nucleus NFAT 
 23binds to regulatory motifs present on the regulatory regions of NFAT target genes 
(Klemm et al., 1997). Inducers of the calcineurin/NFAT pathway involve stimuli that 
cause the release of intracellular calcium, such as VEGF (Armesilla et al., 1999). 
Once NFAT has activated the required genes it is rephosphorylated and 
translocated back to the cytoplasm. The rephosphorylation of NFAT is performed 
by kinases, however, the precise kinase involved is still unknown but possibilities 
include Glycogen synthase kinase-3 (GSK-3), Casein Kinase, MAP kinase kinase 
kinase (MEKK1), Jun N-terminal kinase (JNK2), protein kinase A or p38 (reviewed 
in Kiani et al., 2000).  
 
1.2.4 Calcineurin/NFAT  physiological effects 
1.2.4a Knockout models 
Knockout models are often used to identify pathways where proteins are essential. 
Calcineurin Aα knockout mouse models had decreased T cell activity, reduced 
calcineurin activity in the brain, heart, kidney and spleen and homozygotes were 
sterile, (Halloran et al., 1998). NFAT knockout mouse models had varying 
phenotypic results. NFAT1 knockouts had enhanced B and T cell response. 
NFAT2 knockouts were embryonic lethal due to a defect in the cardiac valve, also 
there was reduced B and T cell proliferation. NFAT3 knockout mice presented with 
defects in the axon outgrowth. NFAT4 knockout caused mildly decreased 
hyperactivation of T cells.  
 
1.2.4b Immune response 
The calcineurin/NFAT pathway is involved in the positive selection of T cells and 
the expression of genes essential for immune response including; IL-2-5, IL-8, IL-
13, GM-CSF and IFN-γ. The promoters of these genes contain binding sites for 
NFAT. Of great importance to the control of immune response by 
calcineurin/NFAT is the transcription partner AP-1. It is a balance between the 
activation of NFAT and AP-1 that regulates the transcription of some cytokine 
genes and determines if the response results in normal T cell activation or T cell 
anergy (Macian et al., 2002). 
 
 
 241.2.4c Angiogenesis 
Angiogenesis is the formation of blood vessels from pre-existing vessels. Upon 
VEGF stimulation it is thought that NFAT is involved in the activation of tissue 
specific genes which are important in regulating angiogenesis. The activation of 
NFAT by VEGF involves dephosphorylation of NFAT by calcineurin (Armesilla et 
al., 1999).  When activated by VEGF, NFATs are involved in inducing the 
expression of genes such as cyclooxygenase (Cox-2) (Tsuji et al., 2001) and 
tissue factor which are important regulators of angiogenesis.  
 
1.2.4d Apoptosis 
Apoptosis is also known as programmed cell death, where a series of events and 
signals generate an apoptotic response. Calcineurin has been shown to 
dephosphorylate the BAD protein, a proapoptotic Bcl-2 protein, resulting in the 
dimerisation of other antiapoptotic Bcl-2 proteins and promoting mitochondrial 
death signals, such as cytochrome C release, caspase activation and 
subsequently apoptosis (Wang et al., 1999). Calcineurin is also important in 
calcium-dependent apoptosis involving the activation of calpain and the 
subsequent cleavage and deactivation of cain/cabin1 resulting in a release of 
calcineurin from inhibition and NFAT activation of pro-apoptotic genes (Kim et al., 
2002). 
 
1.2.4e Bone development 
Calcineurin has been implicated in many aspects of bone maintenance including 
remodelling, formation and resorption (Sun et al., 2005 and Sun et al., 2006). In 
calcineurin Aα knockout models the mice had lower body weights and importantly 
lower tibia and femur weight indicating the importance of calcineurin in bone 
development (Sun et al., 2007). NFAT has been discovered to be critical to cell 
differentiation in both osteoblasts and osteoclasts (Asagiri et al., 2005). The use of 
calcineurin inhibitors such as CsA often results in severe bone loss in the patient, 
although the exact mechanism for this may involve calcineurin-independent 
pathways due to the unspecificity of CsA (Cunningham 2005). 
 
 
 251.2.4f Skeletal muscle development 
NFAT has been found to be expressed in myoblasts and myotubes, with specific 
isoforms playing different roles at different stages of muscle development (Abbott 
et al., 1998). Knockout models showed reduced muscle mass due to a decrease in 
myofiber number and muscle growth (Kegley et al., 2001). Calcineurin is involved 
in the final stage of skeletal muscle differentiation and is also thought to be critical 
in overload induced hypertrophy and muscle fibre type specialisation. (reviewed in 
Schulz and Yutzey, 2004) 
 
1.2.4g Neuronal development 
Calcineurin is important in neuronal cells where it has a role in axonal guidance, 
memory and learning (Mansuy et al., 1998). Calcineurin signalling is involved in a 
positive feedback pathway which may reinforce synaptic connections (Genazzani 
et al., 1999). Calcineurin is also important in the regulation of apoptosis in 
neuronal cells as high expression increases their susceptibility to apoptosis under 
certain conditions, possibly by cytochrome c/caspase 3 mechanisms (Asai at al., 
1999) 
 
1.2.4h Heart development 
Calcineurin/NFAT has been shown to be involved in the later stages of heart 
development, specifically NFAT1 is highly expressed in developing heart valves 
(de la Pompa et al., 1998). NFAT3 and 4 have also been found to be essential for 
mitochondrial maintenance and energy metabolism with knockout mice displaying 
defective cardiomyocyte maturation (Bushdid et al., 2003). 
 
1.2.4i Cell  cycle 
The cell cycle defines the mechanism behind cell growth and division. There are 
four primary stages including G1, gap phase, S, DNA synthesis, G2, gap phase 
and M mitosis. Calcineurin has been shown to be important in the G1 and G2 
phases for the control of cyclin-dependent kinases essential for transcription and 
translation (reviewed in Kahl and Means 2003). 
 
 
 
 261.2.5  Calcineurin/NFAT in disease 
The calcineurin/NFAT pathway has also been described as an essential mediator 
of many pathological conditions as described below. 
 
1.2.5a Cancer 
Cancer is defined as uncontrolled cell proliferation resulting in malignant tumours 
and metastases. It has been discovered that certain cancer types have aberrant 
calcineurin expression thought to aid in cancer progression. A study by Padma et 
al. (2005) demonstrates the importance of calcineurin in cervical cancer, where 
calcineurin activity was found to be downregulated, possibly reducing the degree 
of calcineurin-dependent apoptosis. By suppressing the calcineurin-mediated 
dephosphorylation of BAD with CsA it is possible that cancer progression may 
increase (Hojo et al., 1999). Sanli et al. (2003) have also reported that in certain 
breast cancer cells the activity of calcineurin was markedly reduced due to an 
upregulation of the calcineurin B subunit. The inhibition of calcineurin can lead to 
increases in skin cancer rates indicating that calcineurin may be involved in DNA 
repair (Caforio et al., 2000). However some investigations have revealed that 
rectal cancer and breast cancer rates were decreased in vivo and protection 
against glioblastoma, leukaemia and bladder cancers was found when calcineurin 
activity was reduced (Reviewed in Weischer et al., 2007). There is some 
controversy about the effect of calcineurin in cancer and different results seem to 
be obtained from studies performed In vitro or In vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 271.2.5b Noise-induced hearing loss (NIHL) 
NIHL is defined as the irreversible and cumulative loss of the sensory hair cells of 
the inner ear and damage to their stereocilia caused by overexposure to intense 
sound (Hawkins et al., 1976). This acoustic overstimulation also increases calcium 
concentration in the hair cells which has been shown to activate calcineurin in the 
auditory hair cells (Minami et al., 2004). Uemaetomari et al. (2005) suggest that 
increased calcineurin activity may result in increased calcineurin-dependent 
apoptosis resulting in hair cell death. They demonstrated that treatment with 
calcineurin inhibitors significantly protected mice from acoustic injury. In fact 
Vincente-Torres and Schacht. (2006) have provided convincing evidence that in 
response to noise stimulation, calcineurin dephosphorylates the proapoptotic 
regulator Bcl-2-associated death promoter (BAD) resulting in activation of 
mitochondrion-dependent death cascades and apoptosis. 
 
1.2.5c Diabetes 
Diabetes is a disease caused by a defect in the synthesis, secretion or function of 
insulin. Diabetes was found to be regulated in some way by calcineurin as the use 
of calcineurin inhibitor drugs during transplantation resulted in an increased 
incidence of the patient developing diabetes (Weir 2001). In fact reduced 
calcineurin has been found to lower the intracellular concentration of insulin and 
the transcription of the insulin gene (reviewed in Heit 2007). Complete calcineurin 
inactivation results in diabetes by β-cell failure (Heit et al., 2006). 
 
1.2.5d Pathological Cardiac hypertrophy 
Pathological cardiac hypertrophy is characterised as changes in wall thickness 
and chamber size, gene expression and collagen content resulting from the 
autocrine and paracrine actions of various growth factors induced by stress (Lorell 
et al, 2000). Calcineurin has an important role in transducing the cardiac 
hypertrophic growth response (Molkentin et al., 1998). It was discovered by 
Molkentin et al. (1998)  that overexpression of constitutively active calcineurin in 
the heart of transgenic mice induced severe cardiac hypertrophy, treatment of the 
mice with CsA had the reverse effect further confirming the importance of the 
calcineurin/NFAT pathway in this process.  
 281.2.6 Regulation  of  calcineurin activity 
The main function of calcineurin is to dephosphorylate proteins important in 
cellular regulation, therefore the regulation of calcineurin itself is also essential. 
Partner proteins and modifications that are involved in its regulation are described 
below. 
 
1.2.6a Calcium/calmodulin 
Calcineurin activity it induced by the binding of calcium ions to the regulatory 
domain and this increase in local calcium concentration stimulates the binding of 
calmodulin and subsequent calcineurin activation (Qin et al., 2003). 
1.2.6b Calreticulin 
Calreticulin is involved in binding and buffering calcium in the endoplasmic 
reticulum lumen (Michalak et al., 2002). Since calcineurin activation is dependent 
on intracellular calcium release calreticulin is seen as an important upstream 
regulator of calcineurin function. Calreticulin possibly activates calcineurin activity 
by increasing utilizable calcium release from the endoplasmic reticulum 
(Groenendyk et al., 2004). 
 
1.2.6c Phosphorylation 
Calcineurin is phosphorylated by protein kinase C, casein kinase I and II however 
the activity of the enzyme remains at a similar level to that of its unphosphorylated 
state indicating that phosphorylation of calcineurin has little regulatory value 
(Hashimoto et al., 1989). 
 
1.2.6d Myristoylation 
Calcineurin B has been found to be consistently myristoylated after translation 
indicating that this plays an important role in calcineurin regulation, however, the 
activity of the enzyme is unaltered and the only significance that the modification 
imparts is increased protein stability at low temperatures (Kennedy et al., 1996). 
 
 
 
 
 
 291.2.6e Superoxides 
Calcineurin is inhibited by superoxide oxidation of the iron ion located in the active 
site of the enzyme. This inhibition has been described as reversible indicating that 
it is an important physiological regulatory mechanism for calcineurin and 
calcineurin-dependent processes (Namgaladze et al., 2005) 
 
1.2.7  Exogenous commercial calcineurin/NFAT pathway inhibitors 
Since calcineurin/NFAT is important in many pathological pathways it has 
prompted research and development of drugs to manipulate calcineurin activity 
and its subsequent pathways. There are three calcineurin inhibitors available for 
use as immunosuppressants during transplant therapy. All exert their effects by 
interfering with calcineurin activity and preventing NFAT dephosphorylation 
(Nghiem et al., 2002). 
 
1.2.7a Cyclosporine A (CsA) 
CsA is the most well known of the calcineurin inhibitors. It functions by first binding 
to cyclophilins, isomerase enzymes and this complex then binds to calcineurin 
inhibiting its phosphatase activity (Schreiber et al., 1992). This inhibition is caused 
by the cyclophilin complex blocking the active site of calcineurin resulting in a 
physical inability of calcineurin to dephosphorylate substrates (Schreiber et al., 
1992). 
 
1.2.7b Tacrolimus (FK506) and Pimecrolimus.  
Tacrolimus and pimecrolimus are closely related and differ only slightly in their 
chemical structures and as so inhibit calcineurin in the same way, (Nghiem et al, 
2002). Both bind to FKBPs, isomerases, and this complex then binds to 
calcineurin and inhibits its phosphatase activity by blocking the calcineurin active 
site.  
 
 
 
 
 
 
 301.2.8  Endogenous inhibitors of the calcineurin/NFAT pathway 
The calcineurin/NFAT pathway is involved in many pathological pathways making 
it an attractive target for therapeutic drugs. Unfortunately the use of the exogenous 
inhibitory agents often results in severe side effects such as nephrotoxicity (Myres 
1989), hypertension (Starling et al., 1990), reduced immune response and 
possibly enhancement of patient susceptibility to acquiring cancer (Reviewed in 
Dantel et al., 2007). Lesser side effects include hypertrichosis, tremors and fatigue 
(de Rie et al., 1990). These side effects highlight the need for more selective 
inhibitors and have prompted investigations into more specific endogenous 
inhibitors of the calcineurin/NFAT pathway. A number of cellular proteins have 
been reported to bind and inhibit the calcineurin/NFAT pathway, these proteins are 
described below. 
 
1.2.8a Plasma membrane calcium/calmodulin-dependent ATPase (PMCA) 
PMCA is a calcium pump responsible for maintaining intracellular calcium 
concentration and also plays a role in the regulation of signal transduction 
pathways.  PMCA isoform 4 interacts with calcineurin and inhibits its activity 
resulting in a reduced NFAT activation, possibly due to the tethering of calcineurin 
to a low calcium microenvironment (Buch et al., 2005). 
 
1.2.8b A kinase associated proteins (AKAP-79) 
This family of proteins is responsible for targeting proteins to specific 
microenvironments. AKAP-79 is found specifically in neurons and T cells and 
inhibits the activity of calcineurin and subsequent NFAT activation, thought to 
occur by the tethering of calcineurin to the plasma membrane away from NFAT 
(Kashishian et al., 1998). 
 
1.2.8c FK506-Binding protein (FKBP12) 
FKBP belongs to a class of immunophilins, it interacts with calcineurin and 
anchors it in place for localised dephosphorylation of substrates in particular 
Inositol 1,4,5-triphosphate receptor IP3R, however calcineurin remains active 
(Cameron et al., 1995).  This complex is also important for the inhibition of 
calcineurin by FK506. 
 
 311.2.8d FKBP38 
FKBP38 is involved in mediating the inhibition of calcineurin by FK506 and CsA, it 
has been shown to block calcineurin phosphatase activity and in this way reduce 
calcineurin-dependent apoptosis by aiding binding to Bcl-2 and reducing BAD 
dephosphorylation (Shirane et al., 2003). 
 
1.2.8e Calsarcins 
Calsarcins are a class of calcineurin interacting proteins specifically expressed in 
striated muscle. They interact and co-localise with α−Actinin and are thought to 
tether calcineurin to areas containing a local calcium pool in the sarcomere of 
cardiac and skeletal muscle resulting in regulation of calcineurin activity, it is as yet 
unknown as to the outcome of this regulation (Frey et al., 2000). 
 
1.2.8f Cabin1/cain 
Cabin1/cain has been described as a calcineurin binding/calcineurin inhibitor 
protein (Liu 2003). High mRNA levels of this protein have been found in the brain 
which is the site for maximal calcineurin expression, indicating a functional link 
between the two proteins (Lai et al., 1998). Cabin1/cain inhibits the phosphatase 
activity of calcineurin by binding to a C-terminal domain of the protein (Lai et al., 
1998) during T cell activation (Sun et al., 1998) and during synaptic vesicle 
endocytosis (Lai et al., 2000). 
 
1.2.8g Calcineurin homologous protein (CHP) 
CHP is a novel inhibitor of calcineurin that contains sequence homology with 
calcineurin B and calmodulin (Lin et al., 1999). The mode of inhibition of 
calcineurin by CHP is under debate, theories suggest that it could compete with 
calcineurin B for binding or could serve as a calmodulin antagonist (Liu 2003). 
 
1.2.8h Myocyte-enriched calcineurin interacting protein 
(MCIP/CALP1/calcipressin1)/endogenous calcineurin regulating proteins 
(RCAN)/calcineurin binding protein 1 (CBP1) 
This family of proteins are the only endogenous regulators of calcineurin activity 
conserved from lower to higher eukaryotes indicating their importance as 
 32regulators of this pathway (Kingsbury et al., 2000). At high concentrations this 
family of proteins inhibit calcineurin activity and at low concentrations they activate 
it (Vega et al., 2003). The mechanism for this regulation of calcineurin is under 
debate but theories are that MCIP1 is needed for calcineurin protein folding or 
recognition of substrate (MacKintosh et al., 1996).  
 
The cumulative effect of all these interactions is demonstrated in Fig. 1.2.3. 
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Fig. 1.2.3 Calcineurin/NFAT signalling pathway. (Adapted from Wilkins and Molkentin, 2004) A 
summary of the calcineurin signalling pathway including inhibitory factors of calcineurin and NFAT 
kinases. Green lines indicate activation. Red lines indicate inhibition. 
 
1.2.9 Summary 
The calcineurin/NFAT pathway is involved in many physiological and pathological 
pathways and it is important to characterise its role in these processes and identify 
ways to regulate its activity for therapeutic use. During this project the interaction 
between PMCA and calcineurin will been investigated in different cells types to 
help in fully characterising PMCA as a regulator of signal transduction pathways. 
 
 
 
Calcineurin
NFAT P
NFAT Co-factor 
Cabin1/Cain
CK1 
PKA 
MEKK1 
GSK 
JNK 
p38 
MCIP/ 
Calcipressin
FKBP12/Calsarcins/ 
AKAP79
CHP
Cabin1/Cain Anchoring proteins Plasma 
membrane 
CsA/pimecrolimus/
FK506 
Nuclear 
membrane 
Response genes
 331.3  NITRIC OXIDE SYNTHASE 
 
Nitric Oxide synthases (NOS) are heme containing enzymes, (Babaei and Stewart, 
2002), which convert the amino acid L-arginine to Nitric Oxide (NO) in response to 
mechanical stress and a wide range of agonists. NO is a free radical gas used in 
cells as a signalling molecule, (Pan et el., 2005). It is also involved in regulating 
key physiological pathways as well as being a cytotoxic molecule with low levels at 
or below 100nM producing anti-apoptosis and protection against oxidative stress-
induced cell death and high levels at 400nM or more giving rise to p53 activation 
(Thomas et al., 2004). A study by Qiu et al. (2003) demonstrated that in systems 
with increased microvasculature such as the liver and lungs, eNOS can act to 
prevent metastasis by releasing high levels of NO and triggering apoptosis under 
conditions of cell arrest. 
NO is responsible for maintaining the vasculature, protecting from platelet 
aggregates and leukocyte adhesion and most importantly preventing the 
proliferation of vascular smooth muscle cells. Studies have shown that exogenous 
NO directly affects angiogenesis (Ziche et al, 1994) and its role as a vasodilator is 
inevitably crucial in this function. Many groups are currently trying to target the 
eNOS pathway as a means of regulating blood vessel growth. 
 
1.3.1 NOS  isoforms 
There are three isoforms of nitric oxide synthase; iNOS (inducible NOS) regulated 
by cytokines causing it to produce vast quantities of NO comparable to the other 
isoforms, (Napoli et al., 2006) and calcium/calmodulin regulated nNOS (neuronal 
NOS) and eNOS (endothelial NOS). All three isoforms use NADPH, (Nicotinamide 
adenine dinucleotide phosphate) as an electron donor for the synthesis of NO, 
tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) (Babaei and Stewart, 2002). 
 
 
 
 
 
 
 341.3.1a iNOS 
iNOS (also known as NOSII) is not found in resting cells or tissues and its 
expression is induced by septic shock caused by bacterial lipopolysaccharides and 
cytokines (Schwartz et al., 1999) leading to an increase in systemic NO 
production. Primarily iNOS is expressed in vascular smooth muscle cells (VSMC) 
and only induced under stress or inflammation in the endothelium (Nasser et al., 
2005) 
 
1.3.1b nNOS 
nNOS (also known as NOSI) is constitutively expressed, mainly in neuronal tissue 
and excitable cells. Its function is regulated by calcium/calmodulin and research 
has shown that nNOS forms a macromolecular complex together with Syntrophin 
and PMCA4b that results in negative regulation of its enzymatic activity (Schuh at 
al., 2001, Schuh et al., 2003 and Williams et al., 2006). nNOS control by PMCA4 
has also been implicated in the regulation of cardiac contractility in the heart. 
(Oceandy et al., 2007). nNOS may function as a fail save mechanism when the 
activity of eNOS is affected in certain pathophysiological conditions (Schwartz et 
al., 1999). 
 
1.3.1c eNOS 
eNOS also known as NOSIII is the predominant isoform producing NO within the 
endothelium. This is the isoform on which my project has focussed and as such a 
more detailed review is provided. 
 
1.3.2  eNOS genomic structure 
The gene encoding eNOS is located on chromosome 7, as a single copy in the 
human genome (Marsden et al., 1993). The eNOS gene contains 26 exons and 
introns, including intron 13 which contains the alternative splicing exons for 
production of eNOS splice variants A, B and C during RNA processing, (Lorenz et 
al., 2007) (Fig. 1.3.1).  The functional significance of these splice variants seems 
to be one of activity inhibition by the formation of heterodimers of truncated and full 
length eNOS (Lorenz et al., 2007). 
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Fig. 1.3.1 The genomic structure of eNOS (adapted from Lorenzo et al., 2007 and Li et al., 2002). 
A summary of the promoter region and exons and introns of the eNOS gene. Intron 13 is of interest 
as it contains 3 exons responsible for the 3 known splice variants of eNOS. 
  
The promoter sequence for eNOS contains many transcription factor binding sites 
including p53 and AP-1 confirming the role of eNOS as a possible regulator of 
angiogenesis, particularly under cancerous conditions. (Mortensen et al.,1999 and 
Navarro-Antolin et al., 2000). The regulatory domains of the human eNOS 
promoter also share a 75% homology with bovine eNOS indicating these sites are 
important (Venema et al., 1994).  It has been demonstrated that the stability of 
eNOS mRNA can be altered by various growth factors including VEGF and TNFα 
(Bouloumie et al., 1999 and Yoshizumi et al., 1993). 
 
1.3.3  eNOS protein structure 
The molecular mass of the predicted protein is 133kDa. eNOS exists as a 
homodimer consisting of an oxygenase domain and a reductase domain. The 
oxygenase domain contains binding sites for arginine, haem iron and BH4. The 
reductase domain contains binding sites for NADPH, FAD and FMN with the 
binding site for calmodulin lying between the two domains (Fig. 1.3.2). 
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Fig. 1.3.2 eNOS protein structure (Adapted from Alderton et al, 2001 and Fleming et al., 2003). 
The eNOS protein exists as a homodimer. Each dimer has the same function but uses the 
oxygenase domain of its partner to catalyse the conversion of Oxygen and Arginine to NO and 
Citrulline. eNOS uncoupling can result in lack of NO production. 
 
1.3.4 Regulation  of eNOS activity 
eNOS protein activity is regulated on many levels including transcriptional and 
post-transcriptional control, growth factors, hormones, phosphorylation, 
calcium/calmodulin, protein interactions and physiological conditions. 
 
1.3.4a Transcriptional control 
Transcriptional control of eNOS occurs mainly by the Sp1 and GATA binding sites 
in the eNOS promoter.  These sites are essential for eNOS promoter activity. 
Upon mutation of these sites the activity of the promoter is reduced dramatically 
(Zhang et al., 1995).  There are multiple binding sites for transcription factors on 
the eNOS promoter demonstrating the complexity of eNOS transcriptional 
regulation (See Fig. 1.3.1). Methylation of the eNOS promoter has been shown to  
 37be important in the expression of the eNOS gene in specific cell types particularly 
in non-endothelial cells where the eNOS promoter has been found to be highly 
methylated compared to endothelial cells resulting in an impaired eNOS promoter 
activity (Chan et al., 2004). A negative feedback mechanism for regulation of 
eNOS transcription has been described by Grumbach et al. (2005) which 
hypothesises that NO inhibits NFkB activity, a transcription factor for eNOS itself. 
Also NO can inhibit eNOS activity and modify the expression of the enzyme by 
affecting cGMP levels (Abu Soud et al., 2000 and Vaziri et al., 1999). 
 
1.3.4b Post-transcriptional control 
The stability of eNOS mRNA is an important factor in determining eNOS 
translation. The Untranslated Regions (UTR) of the mRNA construct mediate most 
of the post-transcriptional control. TNFα has been shown to destabilise eNOS 
mRNA by preventing the binding of a cytosolic protein to the 3’-UTR region of 
eNOS mRNA important for the stability of the transcript (Gonzalez-Fernandez et 
al., 2001). Cell proliferation enhancement of eNOS expression has been shown to 
be a completely post-transcriptional mechanism, where the half-life of eNOS 
mRNA was increased by over three times but the transcription of the eNOS gene 
was not altered (Searles et al., 1999). Lipopolysaccharides have been shown to 
have opposite effect on mRNA half-life, (Lu et al., 1996).  FGF and PDGF have 
both been shown to increase the induction of eNOS mRNA (Cuevas et al., 1996 
and Guillot et al., 1999). Under long incubation of eNOS with VEGF, eNOS 
expression has been shown to be upregulated (Hood et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 381.3.5  Regulation of eNOS enzymatic activity 
Regulation of eNOS activity is clearly essential due to its involvement in important 
physiological and pathological conditions. Many mechanisms exist for the 
regulation of eNOS activity, these are described below. 
 
1.3.5a Acylation 
eNOS is the only isoform of NOS acetylated by both palmitate and myristate and 
provides evidence for a preferential localisation to the cell membrane (Feron et al., 
1997). The process of myristoylation is irreversible, however palmitoylation is 
reversible and thought to be one of the mechanisms for regulating the 
translocation of eNOS to and from caveolae (Milligan et al., 1995).  
 
1.3.5b S-nitrosylation 
The NO produced by eNOS itself is used in the S-nitrosylation of Cys 94 and Cys 
99 resulting in eNOS activity inhibition. The reaction occurs in the membrane and 
it is thought to modify binding of substrate or co-factors to eNOS, however the 
exact mechanism has yet to be defined, (Erwin et al., 2005) 
 
1.3.5c Phosphorylation 
The eNOS protein contains multiple sites for eNOS phosphorylation. There are 
currently five known sites on eNOS, four serine residues and one threonine 
residue (Fig. 1.3.3). Three of the four serine residues have a positive effect on 
eNOS activity when phosphorylated. The serine residue Ser
114 is the only 
phosphorylation site in the oxygenase domain of eNOS and its function on eNOS 
activity has yet to be defined as inhibitory or stimulatory, its effects are thought to 
change depending on the type of stimuli causing the phosphorylation (Mount et al., 
2007). Of the other phosphorylation sites Ser
1177 has been studied the most and is 
considered to be the most important phosphorylation site for eNOS activity 
regulation. It is thought that the carboxy-terminal end of eNOS lies between the 
two eNOS monomers and causes autoinhibition when the Ser
1177 phosphorylation 
site is dephosphorylated (Lane et al., 2002). Ser
633 and Ser
615 are both located 
near the calmodulin binding site of eNOS in the FMN binding domain. Ser
633 is 
phosphorylated mostly by PKA, (Boo et al., 2002) and Ser
615 by Akt (Michell et al., 
2002). Interestingly, the Thr
495 phosphorylation site is involved in the inhibition of 
 39eNOS activity.  Thr
495 is phosphorylated by Protein Kinase C (PKC)  and AMP-
activated Protein Kinase (AMPK) thought to result in interference with the binding 
of calcium/calmodulin (Fleming, 2001). Dephosphorylation of Thr
495 occurs via 
Protein Phosphatase 1 (PP1), Protein Phosphatase 2A (PP2A) and calcineurin 
(PP2B), (Thomas et al., 2002). 
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Fig. 1.3.3 Phosphorylation of eNOS (adapted from Kukreja et al., 2007 and Mount et al., 2007). 
eNOS activity is induced by physiological, pathological and pharmacological stimulators. These 
stimulators have an effect on eNOS phosphorylation. There are five sites of possible 
phosphorylation of eNOS three of which are known to activate eNOS activity and NO production, 
one of which has a negative effect on eNOS activity and a phosphorylation of unknown effect, 
possibly biphasic. 
 
Differing effects are produced from the phosphorylation of eNOS and all are 
physiologically relevant. The phosphorylation of eNOS is thought to modulate 
other modifications of eNOS and allow for interaction of NO with other signal 
transduction pathways (Michel et al., 1997). 
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 401.3.6 Physiological  regulation 
As well as regulation by protein modification eNOS activity is also modulated by 
mechanical and hormonal pathways such as shear stress and growth factors. 
 
1.3.6a Shear stress 
Shear stress is the force produced as blood flows through arteries. eNOS is 
regulated by shear stress (Grumbach et al., 2005). Cai et al. (2004) have shown 
that NO production from activation of eNOS by shear stress may be important in 
adaptive arteriogenesis (the development of pre-existing arterioles in to larger 
arterioles or arteries) a process essential to the bypassing of an occluded main 
artery or providing a blood supply to ischemic tissues (Yu et al., 2005). It is 
hypothesised that shear stress induces tyrosine phosphorylation of caveolae 
proteins resulting in a 3-dimensional reorganisation of the caveolae and release of 
eNOS from caveolin-1 inhibition, (Rizzo et al., 1998). Shear stress has also been 
shown to enhance eNOS gene transcription and stabilise eNOS mRNA (Davis et 
al., 2001). 
 
1.3.6b Growth factors and cytokines 
VEGF has two separate effects on eNOS, over the short-term eNOS becomes 
activated, whereas long-term results in upregulation of eNOS expression. VEGF is 
also important in the regulation of angiogenesis and atherosclerosis indicating that 
eNOS is also important to these processes. Angiogenesis, the formation of new 
blood vessels from pre-existing vessels, is mediated by eNOS via VEGF. The 
production of NO from eNOS results in apoptosis inhibition (Rössig et al., 1999) 
and increased endothelial cell proliferation (Ziche et al., 1997) and migration 
(Ziche et al., 1994). Fibroblast growth factor 2 (FGF2) has also been implicated in 
controlling the expression of eNOS via extracellular signal-regulated kinase 2/1 
(ERK2/1), Jun N-terminal kinase (JNK1/2) and phosphatidylinositol-3 kinase/v-akt 
murine thyoma viral oncogene homologue 1 (PI3K/AKT1) activation, important 
members of signal transduction pathways (Meta-Greenwood et al., 2008). 
Transforming growth factor-β1 (TGF-β1) has been shown to increase mRNA levels 
in endothelial cells this increased transcription was a result of TGF-β1 recruitment 
of various important transcription factors (Saura et al., 2002). TNFα has been 
 41shown to significantly reduce the half life of eNOS mRNA by destabilising it 
through enhancing an interaction with translation elongation factor 1 alpha-1 
(eEF1A1) (Yan et al., 2008).  
 
eNOS physiological effects 
eNOS and the production of NO in endothelial cell is important in regulating 
physiological processes such as angiogenesis, vascular tone and apoptosis. 
 
1.3.7a Knockout models 
Studies into the effects of eNOS physiologically have been performed in knockout 
(KO) mice models. The KO mice were found to be hypertensive and lacking 
endothelium-dependent, NO-mediated vasodilation (Huang et al., 1995 and 
Gödecke et al., 2001). KO mice also suffered from hind limb ischemia due to 
impaired arteriogenesis and angiogenesis all indicative of defective VEGF and 
PDGF pathways (Yu et al., 2005).  
 
1.3.7b Angiogenesis 
It has been discovered that angiogenesis is decreased when eNOS activity is 
lowered, this occurs in diseases such as hypercholesterolemia, (Cooke, 2003). 
Also Babei et al. (1998) have shown that when endothelial cells are stimulated to 
differentiate by bFGF the expression of eNOS mRNA and NO production is also 
increased and important in tube formation. The overexpression of eNOS in smooth 
muscle cells in a co-culture model was also shown to promote endothelial cell 
migration and tube formation demonstrating the paracrine effects of NO on 
angiogenesis (Babaei et al., 2002). It is still thought that the mechanism for eNOS 
mediated angiogenic response involves activation of endothelial cell matrix 
proteins such as integrins and adhesion molecules (Dejana et al., 1996 and Koch 
et al., 1995).  
 
 
 
 
 
 
 421.3.7c Vasodilation 
Vasodilation is the relaxation of the vascular smooth muscle resulting in an 
increase in the vessel diameter. NO is involved in this process by activating 
guanylyl cyclases which in turn activate cGMP-dependent kinases thought to be 
important in vasodilation, their exact mechanism of action is still unknown (Surks 
2007).  
 
1.3.7d Apoptosis 
Apoptosis also known as programmed cell death is a defined pathway used by 
cells to control the cell proliferation. Mortensen et al. (1999) have demonstrated 
that high exogenous levels of eNOS produced NO result in increased apoptosis 
and that lower endogenous levels protect against apoptosis, it is hypothesised that 
high exogenous levels may induce apoptosis in invading cells. The mechanism for 
apoptosis induction is implied to be activation of MAPK and subsequent caspase 3 
activation (Kwak et al., 2006). NO species such as peroxynitrite have also been 
implicated in triggering apoptosis in many cell types (reviewed in Pacher et al., 
2007). 
 
1.3.8  eNOS in disease 
Since eNOS is involved in the regulation of many important physiological 
processes abnormal eNOS functioning leads to the progression of many 
pathological conditions. 
 
1.3.8a Heart disease dysfunctional endothelium and the metabolic syndrome 
NO plays a protective role in vascular smooth muscle cells by suppressing 
abnormal proliferation making NO a homeostatic mediator of vascular health. One 
important hallmark for cardiovascular disease (CVD) is the reduced bioavailability 
of NO. The bioavailability of NO can be reduced in many ways, L-arginine 
availability is one such possibility, however, circulating levels of this amino acid are 
thought to be high enough to eliminate it from being a rate-limiting step. Several 
strategies for treatment of CVD have focussed on increasing levels of L-arginine in 
the endothelium and some beneficial results have been produced (Drexler et al., 
1991). Also endogenous inhibitors of eNOS (L-arginine analogues ADMA and L- 
NMMA) compete with L-arginine and it is hypothesised that an increase in their 
 43circulating concentrations may occur in the diseased state (Vallance and Leiper 
2004). A reduction in the availability of the essential eNOS co-factor BH4 is clearly 
an avenue to explore, however studies have been conducted in vitro only and 
demonstrated short term benefits when BH4 levels were increased (Maier et al., 
2000). Finally, NO can be destroyed by reactive oxygen species (ROS). These 
ROS react with NO and result in the production of nitrogen/oxygen species which 
induce protein nitration and lead to coronary heart disease.  
 
1.3.8b Atherosclerosis 
Atherosclerosis is the formation of a plaque made up from the aggregation of fatty 
deposits on the endothelium wall in blood vessels (Fig. 1.3.4). Often caused by 
underlying conditions such as; hypercholesterolaemia, diabetes and hypertension 
(Naseem, K.M. 2005). The formation of atherosclerotic plaques is highly complex, 
however, it is promoted by a lack of NO bioavailability which causes the already 
abnormal endothelial surface to become more susceptible to platelet aggregation 
and adhesion. Under normal, physiological conditions NO is vasoprotective and 
prevents the build up of platelets and inhibits the release of growth factors involved 
in proliferation, such as VEGF and PDGF. Proliferation is a key event in 
atherosclerosis formation. 
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Fig. 1.3.4 The involvement of NO in atherosclerosis formation. (Napoli 2006). eNOS NO production 
inhibits inflammatory signalling such as the C reactive protein (CRP), Tumour Necrosis Factor 
α (TNFα) and subsequent stimulation of vascular cell adhesion molecule 1 (VCAM-1). Atheroma 
are produced when levels of NO are reduced causing platelet aggregation and cause the release of 
asymmetric dimethylarginine (ADMA) resulting in further inhibition of eNOS activity. 
 
1.3.8c Diabetic retinopathy 
Diabetic retinopathy (DR) is a disease manifestation of diabetic microvascular 
disease causing blindness or reduced vision in both eyes of diabetic patients. The 
metabolic pathway involved is still to be elucidated, however, endothelial cell 
dysfunction has been implicated as one of many causes (Khan and chakrabarti, 
2007). DR involves increased angiogenesis, tissue ischemia and vascular  
permeability (Suganthalakshmi et al., 2006). In patients with DR the levels of 
VEGF expression are elevated and this may affect eNOS activity increasing the 
levels of NO which again stimulate VEGF expression in a positive feedback loop. 
 
 
 
 
 451.3.8d Cancer 
Abnormal eNOS expression has been described in certain cancers and it is 
thought to be regulated by cytokines, growth factors and hormones and also by 
tumour suppressor inactivation and oncogene activation, (Geller et al., 1998).   
Tumour-derived eNOS has been shown to promote metastasis and tumour growth 
by releasing NO and stimulating tumour cell migration and angiogenesis (Jadeski 
et al, 1999). Studies have shown that the over-expression of eNOS is crucial for 
angiogenesis and that tumour cells are also capable of producing it. When 
produced from the eNOS of endothelial cells NO affects surrounding cells to 
promote proliferation and migration, when produced by tumour cells NO promotes 
the formation of vessel walls (Pan et al., 2005). VEGF and eNOS exist in cells in a 
positive feedback loop and it has been discovered that in some cells the 
distribution of eNOS and VEGF is co-localised helping to produce a cooperative 
effect (Pan et al., 2005). In malignant melanoma it has been suggested that the 
overexpression of VEGF and eNOS may be novel markers for the disease as their 
expression is normal in benign melanocytes (Tu et al., 2006). In gastric cancer 
eNOS is overexpressed and relates to poor prognosis as it confers cancer 
progression and angiogenesis, therefore, screening for eNOS may be a useful 
preoperative marker (Wang et al., 2005). It is hypothesised that combined 
inhibition of eNOS and the VEGF receptor would be a more effective 
chemotherapy and that their combined over-expression may be used as markers 
for some cancers (Tu et al., 2006). However, Chen et al. (2004) stress that the 
type of tumour must be taken into account before modulating eNOS expression. 
NO plays a very important role in angiogenesis as inhibition by L-NAME results in 
reduced angiogenesis (Gallo et al., 1998). It has also been hypothesised that 
VEGF and eNOS may work in conjunction to increase the number of blood vessels 
reaching tumours (Shang and Li, 2005) research in this field has shown that eNOS 
is present in vascularised regions of tumours in the endothelial cells of capillaries 
(Kucera at al., 2004). NO has also been implicated in reacting with ROS, activating 
telomerase activity, and delaying endothelial cell senescence (Vasa et al., 2000), 
providing evidence of a role for eNOS in the promotion of cancer (Jadeski et al., 
1999). 
 
 
 461.3.9 Protein  interactions 
Protein interactions with eNOS modulate its production of NO. The 
characterisation of the molecular interaction partners that control eNOS activity 
would undoubtedly constitute an essential step in the development of specific 
therapeutic regulators of NO production in endothelial cells. 
 
1.3.9a Calcium/Calmodulin 
eNOS is a calcium/calmodulin-dependent enzyme. Increases in intracellular 
calcium caused by external stimuli result in the formation of the calcium/calmodulin 
complex. This complex displaces an autoinhibitory loop of eNOS resulting in 
eNOS activity upregulation (Fleming et al., 2003). Calcium/calmodulin activation of 
eNOS can be disrupted by CK2 kinase which causes the dissociation of 
calcium/calmodulin from eNOS in a specific manner (Greif et al., 2004).  
 
1.3.9b Caveolin-1 
Caveolin-1 coats the caveolae of blood vessel cells and is an important modulator 
of signalling pathways by compartmentalisation of the cell membrane (Bernatchez 
et al., 2005). Caveolin-1 has been shown to interact with and inhibit eNOS activity 
by blocking the calcium/calmodulin binding site of eNOS (Garcia-Cardena et al., 
1997). This inhibition can be released by displacing caveolin-1 with a 
calcium/calmodulin complex (Feron et al., 1998). The caveolin-1 interaction with 
eNOS is not necessary for eNOS localisation to caveolae (Drab et al., 2001). 
 
1.3.9c Guanine nucleotide binding protein coupled receptors (GPCR) - 
Bradykinin B2 receptor, angiotensin II and endothelin-1. 
Bradykinin B2, angiotensin II and endothelin-1 receptors are G-protein coupled cell 
surface receptors which span the plasma membrane (Hess et al., 1992). The 
ligands of these receptors activate eNOS activity, however, the receptors have 
been found to interact directly with eNOS and inhibit its activity (Marrero et al., 
1999). The mechanism of this inhibition is unknown but does not seem to involve 
disruption of calcium/calmodulin binding as in caveolin-1 inhibition (Ju et al., 
1998).  
 
 
 471.3.9d Heat shock protein 90 (Hsp90) 
Hsp90 is a chaperone protein essential in the folding of proteins and important in 
many signal transduction pathways. Hsp90 binds eNOS when it is tyrosine 
phosphorylated (Harris et al., 2000). Hsp90 enhances the binding of calmodulin by 
increasing Akt-dependent phosphorylation (Fontana et al., 2002). Endoglin is 
expressed on endothelial cell membranes and is responsible for stabilising the 
association of eNOS with Hsp90 (Toporsian et al., 2005). 
 
1.3.9e eNOS interacting protein (NOSIP) and eNOS trafficking inducer protein 
(NOSTRIN) 
NOSIP binds to eNOS and aids the translocation of the enzyme from the plasma 
membrane to the intra-cellular membranes reducing eNOS activity, (Dedio et al., 
2001). NOSTRIN, discovered at the same time as NOSIP, is important in the 
formation of protein associations with eNOS and in vivo aids in the binding of 
caveolin-1 with eNOS (Schilling et al., 2006). 
 
1.3.10 Summary 
eNOS and its production of NO in endothelial cells are clearly an essential part of 
many physiological and pathological processes. It is important to characterise how 
eNOS activity is modulated and whether it can be manipulated as part of a 
therapeutic treatment. This project will look at characterising the involvement of 
PMCA in the regulation of eNOS in endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 481.4  BASIS FOR THIS PROJECT 
Previous work has demonstrated that PMCA regulates the signal transduction 
pathway of calcineurin/NFAT (Buch et al., 2005). This work provided evidence for 
the important role played by PMCA in inhibiting the activity of calcineurin in 
mammalian cells and its subsequent signal transduction pathway. The hypothesis 
that PMCA inhibits calcineurin activity by tethering the calcium/calmodulin-
dependent protein to a low calcium microdomain created by the pumps calcium 
extrusion function, was raised. 
Other work by Schuh et al. (2001) demonstrated that PMCA was also responsible 
for regulating the activity of nNOS in cardiac cells and the subsequent NO 
signalling pathway, highlighting the novel role of PMCA as a regulator of signal 
transduction pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 491.5  AIMS OF THIS PROJECT 
Previous research suggests that PMCA plays an important role as a regulator of 
signal transduction pathways. The aim of this project was to further define the role 
played by PMCA in signal transduction pathways in different cells types.  
Further characterisation of the interaction between PMCA and calcineurin in 
various cells types to determine any isoform-, cell type-specific regulation will be 
investigated. The expression profile of PMCA in breast cancer cells has recently 
been established, therefore, the effect on the calcineurin/NFAT signal transduction 
pathway will be assessed. 
The hypothesis that PMCA may be important in regulating calcium/calmodulin-
dependent proteins and has already been shown to interact with NOS, prompted 
the investigation for its role in regulating calcium/calmodulin-dependent eNOS in 
endothelial cells. To further investigate the role of PMCA as a regulator of signal 
transduction pathways in endothelial cells any interaction with calcineurin will also 
be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 501.6 HYPOTHESIS 
The overall hypothesis for this project is that PMCA is an inhibitor of the activity of 
the calcium/calmodulin-dependent proteins calcineurin and eNOS and their 
subsequent signal transduction pathways in mammalian cells. This work will 
provide further circumstantial evidence in support of the hypothesis that PMCA 
inhibits the activity of calcium/calmodulin-dependent proteins by tethering them to 
a low calcium microdomain created by the pump itself (fig 1.6.1). 
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Fig. 1.6.1 Hypothetical involvement of PMCA in the regulation of calcium/calmodulin-dependent 
proteins and their subsequent signalling pathways. 
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2. CHAPTER TWO:  
 
GENERAL METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52(All materials were produced by Sigma-Aldrich unless otherwise stated. See 
appendix section A2 for address details on each company mentioned and 
appendix A3 for details of solutions used in the methods section 2.1). 
 
2.1  Cell culture methods 
 
2.1.1  Primary cells and cell lines 
Each primary cell culture and cell line was handled separately from each other to 
avoid cross contamination. The morphology of each cell line was monitored at 
each passage and the use of primary cells was stopped at the point of 
senescence. 
 
2.1.2  Cell culture medium 
Hek293 cells (Human epithelial Kidney cells) and MCF-7 (human breast 
adenocarcinoma) were obtained from the ATCC (American Type Culture 
Collection) and were grown in Dulbeccos Modified Eagles Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 5% HEPES buffer (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 1% penicillin/streptomycin (100x), 
1% L-Glutamine (200mM) and 1% non-essential amino acids (NEM).  
EAhy926 cells (endothelial cell line derived from the fusion of Human Umbilical 
Vein Endothelial Cells, HUVEC, with A549 carcinoma cell line) were grown in 
RPMI supplemented with 10% FBS, 1% penicillin/streptomycin (100x) and 1% L-
Glutamine (200mM).  
HUVEC were cultured in Endothelial Growth Medium 2, (EGM-2) (Cambrex) 
supplemented with the EGM-2 growth factors kit (Cambrex) containing 10mL FBS, 
1μg/mL Hydrocortisone, 1ng/mL human Fibroblast Growth Factor-B (hFGF-B), 
0.5ng/mL Vascular Endothelial Growth Factor (VEGF), 20ng/mL R3-Insulin-like 
Growth Factor-1 (R3-IGF-1), 1μg/mL Ascorbic acid, 5ng/mL Human Epidermal 
Growth Factor (HEGF), 1μg/mL Gentamycin (GA-1000), 22.5μg/mL Heparin, 
10000 U/mL penicillin and 10mgmL streptomycin.  
 
 
 
 53The EAhy926 cell line was the generous gift of Dr Lora-Jean S. Edgell (University 
of North Carolina, Chapel Hill, North Carolina, USA) and HUVEC cells were 
purchased from Cambrex.  
 
2.1.3 Freezing  and  thawing of cells 
Primary cells, such as HUVEC, were frozen on arrival and the cell lines were 
frozen down at various time points so that a stock was maintained. Cells were 
prepared for freezing by trypsinisation and centrifugation (explained in section 
2.1.4). The pellet was resuspended in freezing solution containing 90% FBS and 
10% Dimethyl Sulphoxide (DMSO). DMSO is a cryoprotectant and stops the 
formation of crystals during freezing that may damage the integrity of the cells. 
Cells were stored at -80°C for one week to allow for slow freezing and then 
transferred to liquid nitrogen until needed. Cells were defrosted by rapid thawing 
and resuspended in pre-warmed medium. The cell suspension was centrifuged at 
1400 rpm for four minutes and the supernatant containing DMSO, which is toxic to 
cells, was aspirated away. The cells were then treated as normal.  
 
2.1.4 Passaging  cells 
Each cell line and primary cells were passaged when they reach 80-100% 
confluence. The cell medium was aspirated away and the cells were washed with 
1x Phosphate Buffered Saline (PBS) to remove any remaining FBS that may 
inactivate the trypsin. This PBS was aspirated away and trypsin-Ethylene Diamine 
Tetra acetic Acid (Trypsin-EDTA) (2.5g/L Trypsin and 0.2g/L EDTA) was added 
and left for approximately five minutes until all cells had detached. Depending in 
the cell type, complete pre-warmed medium was then added and the cell 
suspension was collected and centrifuged at 1400rpm for five minutes to pellet the 
cells. The supernatant was aspirated away and the pellet was resuspended in pre-
warmed medium and transferred to a tissue culture flask. The amount of medium 
used depended on the size of the flask, 175mL flask requires 30mL of medium, 
75mL requires 20mL and a 25mL flask requires 5mL. 
 
 
 
 
 542.1.5 Cell  quantification 
Cell density was determined so that results obtained were consistent and cells 
were at confluence. The cells were passaged until they needed to be transferred 
to a new tissue culture flask, at this point 1mL of the cell suspension was removed 
and 20μL of this solution was used to determine cell density. A Neubauer 
haemocytometer was used and the cell number was determined by counting the 
number of cells in two 4x4 grids and taking an average. The 4x4 grid represents 
the number of cells x 10
4 in 1mL of cell suspension. 
 
2.1.6  Transfection of mammalian cells 
All Lipofectamine transfection efficiencies were confirmed using a ß-galactosidase 
expression plasmid and Amaxa transfections efficiencies were confirmed using a 
GFP expression plasmid as positive controls. 
 
2.1.6a(i) Lipofectamine  method 
For immunoprecipitation experiments 4.5x10
6 HEK293 cells were plated in 100mm 
tissue culture plates the day before transfection. 15μg of each plasmid was 
incubated with 25μL of cationic lipid-based transfection reagent, Lipofectamine 
(invitrogen) per plate and made up to a final volume of 500μL with Opti-mem 
(invitrogen). This was incubated at room temperature for thirty minutes to allow for 
the formation of DNA-lipid complexes. The solution was then pipetted onto the 
cells and swirled to mix. The cells were left overnight. The following morning the 
medium was removed, the cells were washed with 1x PBS to remove any 
Lipofectamine, as this is toxic to cells and 10mL of fresh medium was added. The 
cells were incubated at 37°C overnight. 
 
2.1.6a(ii)  Luciferase gene reporter analysis 
For Luciferase gene reporter analysis 1x10
6 HEK293 cells were plated per well in 
a six well plate the day before transfection. The required amount of plasmid (up to 
5μg) was incubated with 5μL of Lipofectamine per well and made up to a final 
volume of 520μL with Opti-mem. This solution was incubated at room temperature 
for 30 minutes to allow for the formation of DNA-lipid complexes. The solution was 
then pipetted onto the cells and swirled to mix. The cells were left overnight. The 
 55following morning the medium was removed along with any dead cells. Viable cells 
were washed with 1x PBS to remove any Lipofectamine and 5mL of fresh medium 
was added. The cells were incubated at 37°C overnight. 
 
2.1.6b AMAXA method 
Cells were quantified (as described in section 2.1.5) and pelleted. 0.5x10
6 HUVEC 
cells were then resuspended in Nucleofector solution (Amaxa AG), 100μL required 
per transfection. Up to 5μg of plasmid was added to the cell solution and 
transferred to a nucleofector cuvette. Cells were electroporated according to the 
manufacturer instructions. Transfected cells were resuspended in 5mL of fresh 
medium and plated onto a six well plate. After overnight incubation the medium 
was aspirated away removing any dead cells and viable cells were incubated for 
another 24 hours in 5mL of fresh medium. 
 
2.2  Methods for DNA preparation and cloning 
2.2.1  Polymerase Chain Reaction (PCR) 
All PCR products were sequenced prior to use. 
The programme used for each reaction included an initial denaturation step of 
94°C for two minutes, thirty cycles of denaturation at 94°C for one minute, primer 
annealing at a temperature relevant for the primers for one minute and elongation 
at 72°C for one minute thirty seconds. The programme ended with a final 
elongation at 72°C for ten minutes. The samples were kept at 4°C until needed.  
A high fidelity PCR master kit from Roche (Roche Diagnostics Limited) was used 
to setup PCR reactions which contained 4mM of each deoxynucleoside 
triphosphates (dNTPs), 3mM Magnesium Chloride (MgCl2), Taq DNA and Tgo 
DNA polymerases and reaction buffer. A standard reaction included 25μL of the 
master mix described above, 10-500ng of template DNA, 200ng/μL of each 
specific forward and reverse primer and PCR grade dH2O to a final volume of 
25μL. For each reaction different primers and template DNA were used. The 
annealing temperature of the primers was determined using the following 
equation: 
Tm = [(G + C)4 + (A +T)2] -4°C 
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ordered from VHBio. The Primer concentration was determined by 
spectrophotometry. The single stranded DNA was measured at 260nm. To 
calculate nucleotide concentration 1 optical density unit (OD) at 260nm 
corresponded to 20μg of single stranded DNA. 
 
2.2.2  Agarose Gel Electrophoresis (AGE) 
Agarose gel solution was prepared using electrophoresis grade agarose 
(Invitrogen) and 1x Tris-Acetate-EDTA (TAE) buffer (invitrogen). Ethidium Bromide 
(EtBr) (invitrogen), an intercalating agent which fluoresces when excited by light in 
the ultraviolet spectrum, was also added to allow visualisation of the DNA. The 
quantity of agarose and ethidium bromide added to TAE buffer was dependent on 
the size of the DNA and the size of the gel being prepared. A 2% w/v gel was 
prepared for DNA below 1000 base pairs (bp). 0.7% w/v gel was prepared for 
anything over 1000bp. For a 50mL gel 2μL of 10mg/mL EtBr was used and for a 
100mL gel 3.5μL was used. The gels were electrophoresed at 80 Volts for a 0.7% 
w/v and 120 Volts for a 2% w/v. Samples were prepared by addition of 6x loading 
buffer containing bromophenol blue and glycerol. The samples were loaded at a 
volume of 12μL/well. In addition to the samples a 100mg/mL 1 kilobase (kb) DNA 
ladder (invitrogen) was used as a DNA length marker loaded at a volume of 
12μL/well. The length of time the gels were electrophoresed was dependent on the 
size of the DNA but was approximately thirty minutes. The gels were viewed under 
ultraviolet light in a syngene genesnap gel documentation system (Geneflow). 
 
2.2.3 DNA  precipitation 
DNA produced from PCR experiments was precipitated using 5M Sodium Acetate 
(NaAc) at a volume 1/10
th that of the volume of the solution containing the DNA 
and 100% ice cold Ethanol at a 2.5x volume of the volume of the solution 
containing the DNA. The precipitating DNA was incubated at -20°C overnight and 
centrifuged at 13000rpm for seven minutes to pellet the DNA. The supernatant 
was discarded and the pellet was resuspended in autoclaved dH2O to the required 
volume. 
 
 572.2.4  Restriction enzyme digestion of PCR product and plasmid 
DNA was digested using restriction enzymes from Promega in a reaction 
containing the relevant buffer, 1x 10mg/mL Bovine Serum Albumin (BSA), DNA 
sample and dH2O. The digestion reaction was incubated at the corresponding 
temperature in a water bath overnight. The following morning an additional aliquot 
of fresh restriction enzyme was added to the reaction and samples were incubated 
for an additional three hours. All restriction enzymes and buffers were purchased 
from Promega. 
 
  Buffer Temperature  (°C) 
Restriction enzyme digest pair    
EcoRI - BamHI  E  37 
HindIII-BamHI E  37 
HindIII-BglII B  37 
EcoRI - XbaI  H  37 
 
Fig 2.2.1. Table of restriction enzymes, buffers and optimum digestion temperatures. 
 
2.2.5 Preparative  gel 
A large agarose gel was prepared, the percentage depended on the size of the 
DNA, three wells were joined together to allow 60μL of sample to be loaded. 1Kb 
ladder was used to allow identification of the DNA size. 
 
2.2.6 Purification  of DNA from agarose gels 
DNA was visualised by using a UV light box and excised from the gel using a 
scalpel blade. The excised DNA was transferred to a microfuge tube. A PCR gel 
clean up wizard kit (Promega) was used to elute the DNA. 300μL of membrane 
binding solution was added (10μL/10μg) and the agarose containing DNA was 
incubated at 50°C-60°C for ten minutes, vortexing occasionally to dissolve the 
agarose. The agarose/DNA solution was transferred to a silica resin minicolumn 
and incubated for one minute to allow the DNA to attach to the column resin. The 
column was centrifuged for one minute at 13000rpm, the eluate was discarded 
 58from the collection tube. 700μL of wash buffer was added and the column was 
centrifuged at 13000rpm and the eluate was discarded again. The column was 
washed with 500μL of wash buffer and after centrifugation 50μL of nuclease free 
water was added and allowed to incubate for one minute. The column was 
centrifuged at 13000rpm for one minute and the eluate containing the DNA was 
transferred to a fresh microfuge tube and stored at 4°C until needed. 
 
2.2.7 Plasmid  dephosphorylation 
Plasmids were dephosphorylated before ligation to reduce the amount of plasmid 
that may re-ligate. Precipitated plasmid DNA was resuspended in 80μL of dH2O. 
10μL of alkaline phosphatase buffer was added and 5μL of 1U/mL shrimp alkaline 
phosphatase (Promega). The reaction was incubated at 37°C in a water bath for 
thirty minutes. Then another 5μL of alkaline phosphatase were added to the 
reaction mixture and that was further incubated for thirty minutes or more. A 
preparative agarose electrophoresis gel was carried out to purify the plasmid. 
 
2.2.8 Plasmid  ligation 
Insert DNA and plasmid vector DNA were incubated at a 3:1 Molar ratio, 
respectively, with bacteriophage T4 DNA ligase (3U/mL) and 1x ligase buffer 
(Promega) at 15°C overnight.  
 
2.2.9 Plasmid  transformation 
200μL Competent Escherichia Coli (E.coli), JM109 (Promega) were incubated with 
plasmid DNA or the ligation reaction at 4°C for ten minutes. The mixture was then 
incubated at 42°C for two minutes. This heat shock caused the bacterial cell wall 
to perforate and allowed the DNA to enter the cell. 300μL of fresh Luria Broth (LB) 
were added to the solution that was incubated at 37°C for one hour to enable the 
bacteria to produce antibiotic resistance. Transformed bacteria were plated on 
LB/Agar plates containing ampicillin (100μg/mL) and incubated overnight at 37°C. 
 
2.2.10 Minipreparation 
Individual colonies were selected and aseptically transferred to 11mL of LB culture 
media containing ampicillin (100μg/mL). The culture was incubated on an orbital 
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microfuge tube as stock. The rest was then centrifuged at 3500rpm for ten minutes 
and the bacterial pellet was resuspended in 250μL of P1 (resuspension buffer) 
from a QIAGEN spin miniprep kit from (QIAGEN). The bacteria were lysed by the 
addition of 250μL of P2 (lysis buffer) and inverted for five minutes. Lysis was 
stopped with 350μL of P3 (Neutralisation buffer). The lysed bacteria were 
centrifuged at 13000rpm for ten minutes. The supernatant containing the plasmid 
DNA was transferred to a purification column and incubated for one minute to 
allow the plasmid DNA to attach to the column resin. The column was centrifuged 
at 13000rpm for one minute and the eluate was discarded. 700μL of wash buffer 
was added to the column and centrifuged at 13000rpm for one minute. The 
column was transferred to a fresh collection tube and 50μL of elution buffer was 
added and allowed to incubate for one minute. The column was centrifuged at 
13000rpm for one minute and the eluted solution containing plasmid DNA was 
transferred to a fresh microfuge tube. 
 
2.2.11 Maxipreparation of plasmids 
400mL of LB culture media containing ampicillin (100μg/mL) was innoculated with 
200μL of bacterial culture that contained the specific plasmid and incubated at 
37°C in an orbital shaker overnight. The culture was then centrifuged at 3500rpm 
for ten minutes and the pellet was resuspended in 10mL of resuspension buffer 
from a maxiprep kit (Qiagen). The bacteria were then lysed using 10mL of lysis 
buffer by inversion for five minutes. 10mL of neutralisation buffer was then added 
and inverted for five minutes. The mixture was then centrifuged at 11400rpm for 
twenty minutes to pellet the genomic DNA. The supernatant was transferred to a 
pre-prepared column, (10mL of equilibration buffer was added previously), and 
allowed to run completely through the column. 60mL of wash buffer was added to 
the column and allowed to run through. 15mL of elution buffer was added to the 
column and the eluate was mixed with isopropanol to precipitate the plasmid DNA. 
This was centrifuged at 11400rpm for thirty five minutes to pellet the plasmid DNA. 
The pellet was resuspended in 300μL of Tris-chloride/EDTA buffer (TE). The 
plasmid was then restriction enzyme digested to confirm the presence of the 
correct DNA insert. 
 602.3  Methods for protein analysis 
2.3.1 Protein extraction from cultured cells 
The medium was removed and discarded from the cells and the cells were 
washed with 1x PBS. The cells were then lysed in RIPA buffer containing; 2mL of 
10x PBS, 2mL of 10% Igepal, 1mL of 10% Sodium Deoxycholate, 200μL of 10% 
Sodium Dodecyl Sulphate (SDS), 20μM PhenylMethaneSulphonylFluoride 
(PMSF), 500ng/mL pepstatin A, 500ng/mL leupeptin, 1μg/mL aprotinin made up to 
20mL with dH2O.  The cells and RIPA buffer were incubated at 4°C on an orbital 
shaker for ten minutes. The lysed cells were then transferred to a microfuge tube 
and centrifuged at 13000rpm for one minute to remove any precipitated DNA. The 
supernatant was retained and stored at 4°C overnight or at -20°C until needed, 
protein quantification was performed at this step if required. 
 
2.3.2 Protein  quantification 
Proteins were quantified using the BCA protein assay kit-(reducing agent 
compatible) from (Pierce) following the manufacturer instructions. 
 
2.3.3 Immunoprecipitation 
Agarose A beads (Roche) were prepared by centrifugation at 3000rpm for two 
minutes and washing with RIPA buffer twice. The protein cell lysate was incubated 
with 100μL of beads for every 1mL of cell lysate for one hour at 4°C with rotation. 
This step was called pre-cleaning and was necessary to remove any particles in 
the protein lysate that may have unspecifically bound to the agarose A beads, to 
improve the specificity of the immunoprecipitation. The agarose A beads and 
protein lysate solution was centrifuged at 3000rpm for two minutes. If necessary 
12μL of supernatant was aliquoted into a fresh microfuge tube and mixed with 
48μL of 4x protein loading buffer (invitrogen), for the analysis of plasmid 
expression levels. The remaining supernatant was incubated with 40μL of fresh 
agarose A beads and specific antibody overnight at 4°C with rotation. The 
immunoprecipitation mixture was then centrifuged at 3000rpm for two minutes and 
the supernatant was discarded. The remaining agarose A beads, protein and 
antibody complexes were washed with RIPA buffer twice to remove any unbound 
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and stored at -20°C until needed. 
 
2.3.4 Purification of Flag-PMCA2(462-684) recombinant protein 
HEK293 cells were transfected with p3xFlagPMCA2(462-684) using the 
lipofectamine method described in section 2.1.6a and cell lysates were incubated 
with anti-Flag
®-M2 affinity gel agarose beads overnight. The immunoprecipitated 
protein was eluted with Flag peptide (125 ng/µl) in RIPA buffer according to the 
manufacturer’s instructions. 
 
2.3.5 Polyacrylamide  gel  electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis requires two types of gel, a stacking gel and a 
resolving gel. The stacking gel was prepared using 1.4 mL of Bis-acrylamide, 
(Geneflow Ltd) 2.5mL of 4x 1.5M Tris buffer pH 6.8, 6.1mL of dH2O, 100 μL of 
10% Ammonium persulphate (APS) and 60 μL of N,N,N,N-tetramethyl-
ethylenediamine (TEMED) added last. The resolving gel was prepared using 
3.75mL of 4x 1.5M tris buffer pH 8.8, 100 μL 10% of APS, 60 μL of TEMED and 
depending on the size of the protein the concentration of Bis-acrylamide and dH2O 
was altered. For a protein over 100kD a 6% gel was required containing 2.8mL of 
Bis-acrylamide and 7.35mL of water. For a protein under 100kD a 12% gel was 
required containing 5.6mL of Bis-acrylamide and 5.65mL of dH2O. The resolving 
gel was prepared first and placed into the PAGE apparatus. 1ml of 100% Butanol 
was added to the top of the resolving gel to remove any bubbles that may have 
formed. The gel was then allowed to polymerise for ten minutes. The Butanol was 
washed away using dH2O. The stacking gel was then prepared and placed on top 
of the resolving gel. Proteins were denatured by heating at 100°C for two minutes 
and centrifuged briefly to gather any evaporated sample. 20 μL of each sample 
were loaded per well and 12 μL of 1x protein marker Seeblue plus2 (Invitrogen) 
were added to the first and last wells. The gel was electrophoresed at 200V for 
one hour in running buffer (0.25M Tris base, 1.92M glycine and 1% w/v SDS) 
(Geneflow).  
 
 
 622.3.6 Western  Blotting 
Proteins were transferred from the gel to a nitrocellulose membrane by 
electrophoresis at 35V for ninety minutes in transfer buffer (0.2M Tris base/1.5M 
glycine/20% methanol). The membrane was removed and placed into a 5% w/v 
semi-skimmed milk solution prepared in 1x Tris Buffered Saline (TBS) solution. 
This was incubated overnight at 4
°C on a shaker. The milk solution was discarded 
and the membrane was washed with TBS-0.1%TWEEN20. The membrane was 
incubated with the required amount of primary antibody for three hours. The 
membrane was washed again as before and, if necessary, was incubated with the 
required amount of secondary antibody for one hour. The membrane was washed 
again as before and transferred to the dark room. The antibody dilutions used are 
detailed in fig. 2.3.1. 
 
   Company Useage Dilution/concentration  Incubation 
period (Hrs) 
Antibody             
α-PMCA1 (rabbit)  Swant  WB/IP  WB (1:2000)/IP (1:100)  3 
α-PMCA2 (rabbit)  Swant  WB/IP  WB (1:2000)/IP (1:100)  3 
α-PMCA3 (rabbit)  Swant  WB/IP  WB (1:2000)/IP (1:100)  3 
5F10 (mouse)  Abcam  IP  IP (1:1000)  overnight 
α-Luc (mouse)  Promega  IP  IP (1:1000)  overnight 
α-calcineurinA (mouse)  Sigma  IP  IP (1:1000)  overnight 
α-Flag-hrp   Sigma  WB  WB (1:10000)  3 
α-eNOS (rabbit)  Sigma  WB/IP  WB (1:1000)/IP (1:100)  3/overnight 
α-eNOS (mouse)  Zymed  WB   WB (1:1000)   3 
α-rabbit-hrp   Sigma  WB  WB (1:5000)  1 
α-mouse-hrp   Sigma  WB  WB (1:5000)  1 
WB: Western Blot         
IP: Immunoprecipitation         
 
Fig. 2.3.1.  Details of Antibody dilutions, source, usage and incubation period. 
 632.3.7  Western blot development 
Membranes were incubated for one minute with a mixture of 1mL solution A and 
1mL solution B from an EZ chemiluminescence kit (geneflow). Antibodies were 
detected by exposing the membranes to autoradiographic film (Kodak). 
 
2.4 Functionality  assays   
2.4.1 cGMP  assay 
Cells were transfected with 5μg of each plasmid required. Cells were saturated 
with L-arginine (30 min, 1 mM) and nascent NO was stabilized by addition of 
superoxide dismutase (SOD, 100 U/ml of culture medium) (Sigma-Aldrich) five min 
before lyses. In parallel, 3-isobutyl-1-methylxanthine (IBMX, 1 mM; Sigma-Aldrich) 
was added to the culture five min before lyses (to inactivate phosphodiesterase 
activity), and NO synthesis was induced by addition of 0.5 µM A23487 calcium 
ionophore three min before lyses. Cells were washed three times in cold 1x PBS 
and resuspended in buffer A from a cGMP enzymeimmunoassay biotrak (EIA) 
system (Amersham). Cells were resuspended in enough volume to allow protein 
quantification and duplicate cGMP assay, up to 1 x 10
6cells/mL. cGMP was 
measured according to the manufacturer’s instructions. A thermo lab systems 
multiskan ascent machine was used to measure the optical density of the final 
samples. 
 
2.4.2 Luciferase  assay 
Cells were transfected with the required plasmid and the ratio of the pNuclear 
Factor of Activated T-cells-Luciferase (pNFAT-TA-Luc) plasmid (Clontech) to the 
plasmid of interest was 1:3 respectively. Cells were stimulated with phorbol 
myristate acetate (PMA) (20 ng/ml) and the calcium ionophore A23187 (1 μM) for 
sixteen hours and luciferase activity determined using a kit from Promega. Cells 
were washed with cold PBS 1x and lysed with 100μL of 1x luciferase lysis reagent 
(Promega) for ten minutes. 100μL of luciferase substrate (Promega) was 
incubated with 20μL of sample and the relative luciferase units (RLU) were 
determined using a Berthold detection systems Sirius (Geneflow) for thirty 
seconds.   
 
 642.5 Plasmids used 
2.5.1 Novel  plasmids 
Plasmids that were created during this project are described in sections 3.3.1 and 
4.5.1. 
 
2.5.2  Plasmids created previously or purchased 
pNFAT-TA-Luc (Clontech) 
P3xFlagcmv7.1 and pFlag5b (Sigma) 
pcDNA3 (Invitrogen) 
pcDNA3-hPMCA2b contains the human PMCA2b cDNA and was a gift from Prof. 
Carafoli (University of Padova, Italy) 
pFlag-PMCA4-(428-651) has been described previously (Buch et al., 2005) 
pcDNA3-PMCA1 has been described previously (Holton et al., 2007) 
pcDNA3-eNOShumanA contains the human eNOS cDNA and was a gift from Prof. 
S Lamas (Centro de Investigaciones Biologicas, Madrid, Spain) 
 
2.6 Statistical methods 
All data for the luciferase assays and cGMP assays were analysed using an 
unpaired student T-test, as the experiments were carried out independently of 
each other, with their own controls and samples were unpaired. All data analysis 
was performed using Graphpad prism software. 
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3. CHAPTER THREE RESULTS 
 
PMCA AS AN INHIBITOR OF THE CALCINEURIN/NFAT SIGNAL 
TRANSDUCTION PATHWAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 663.1 Introduction 
Dr Armesilla’s group has recently reported an inhibitory interaction between 
ectopically expressed human PMCA4b and calcineurin A in HEK293 cells (Buch et 
al., 2005). In this thesis the interaction between endogenous PMCA and 
calcineurin A in human breast cancer cells and endothelial cells has been 
investigated further to extend the initial observations with PMCA4b to other PMCA 
isoforms and cell types. 
Appendix, section A1 demonstrates the specificity of the primary antibodies used. 
 
3.2 Analysis of the interaction PMCA-calcineurin in MCF-7 human breast 
adenocarcinoma cells 
To analyse the interaction between endogenous PMCA1, 2 or 4 and calcineurin A, 
a monoclonal anti-calcineurin A antibody (Sigma) was used to immunoprecipitate 
protein extracts isolated from human MCF-7 breast adenocarcinoma cells. A 
western blot was then performed on the immunoprecipitated proteins using 
isoform-specific anti-PMCA antibodies (Swant). 
A faint but reproducible band corresponding to PMCA4 was detected in samples 
probed with a rabbit anti-PMCA4 antibody (Fig. 3.2.1, upper panel). This result 
suggests that calcineurin A and PMCA4 interact weakly in MCF-7 cells. High 
levels of PMCA4 were found in MCF-7 proteins immunoprecipitated with the 5F10 
anti-PMCA monoclonal antibody (Fig. 3.2.1, upper panel), thus confirming that low 
affinity of the anti-PMCA4 antibody or low expression of PMCA4 in MCF-7 cells 
were not responsible for the weak detection of PMCA4 co-precipitated with 
calcineurin. 
Western blot performed using an anti-PMCA2 antibody revealed high levels of co-
precipitated PMCA2 (Fig. 3.2.1, middle panel). This result suggests a strong 
interaction between endogenous calcineurin A and PMCA2 in MCF-7 cells. 
PMCA1 failed to be co-precipitated with calcineurin A, as demonstrated by lack of 
PMCA1 detection during western blot analysis of the precipitated proteins using an 
antibody recognising specifically PMCA1 (Fig. 3.2.1, lower panel). This result 
suggests that PMCA1 and calcineurin do not interact in MCF-7 cells. The lack of 
interaction between PMCA1 and calcineurin A was not due to low expression of 
PMCA1 as control immunoprecipitation performed with MCF-7 protein extracts 
using the 5F10 anti-PMCA monoclonal antibody, and subsequent western blot with 
 67the anti-PMCA1 specific antibody, precipitated high levels of PMCA1 (Fig. 3.2.1, 
lower panel). 
The selectivity of the interactions was confirmed by performing control 
immunoprecipitations with an irrelevant antibody (anti-Luciferase) (Promega) in 
which no protein was precipitated (Fig. 3.2.1). 
To summarise, these results demonstrate that the interaction between 
endogenous PMCAs and calcineurin A is isoform specific in breast cancer cells. 
They suggest that PMCA2 is the predominant isoform interacting with calcineurin 
A in MCF-7 cells, although calcineurin A also interacts weakly with PMCA4.   
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Fig. 3.2.1   The interaction between endogenous PMCA and calcineurin A in MCF-7 human breast 
adenocarcinoma cells is isoform specific. The interaction between PMCA and calcineurin in MCF-7 
cells was demonstrated by co-precipitation of PMCA2 or –4 (but not PMCA1) and calcineurin from 
protein extracts immunoprecipitated with an antibody against calcineurin A. (α-CnA) anti-
calcineurin A monoclonal antibody, (5F10) anti-PMCA monoclonal antibody, (α-luc) anti-luciferase 
antibody. Western blots of immunoprecipitated proteins were probed with antibodies specific for 
PMCA1, -2, or -4 (Swant) to detect PMCA1 (WB: α-PMCA1), PMCA2 (WB: α-PMCA2) and PMCA4 
(WB: α-PMCA4) respectively. A representative result from three independent experiments is 
shown. 
 
The strong interaction between PMCA2 and calcineurin A prompted the mapping 
of the domain of PMCA2 implicated in the interaction. 
 
 
 
 
 
 
 693.3 Determination of the domain of PMCA2 interacting with calcineurin A 
 
Dr Armesilla’s group has previously reported that the region 428-651 of human 
PMCA4b is implicated in the interaction with calcineurin A (Buch et al., 2005). 
Comparison of the equivalent region in PMCA2b revealed a high degree (76%) of 
amino acid homology suggesting that this region of PMCA2 might be implicated in 
the interaction with calcineurin A. To test this possibility, we have generated Flag-
tagged fusion proteins including this and other regions of human PMCA2b. 
 
3.3.1  Generation of Flag-tagged expression plasmids for identification of the 
PMCA2b domain interacting with calcineurin. 
 
3.3.1a Cloning strategy 
In order to generate expression vectors encoding Flag-tagged truncated proteins 
of human PMCA2, the corresponding fragments of human PMCA2b cDNA (gene 
bank accession number: NM_001683) were amplified by PCR and cloned into the 
expression vector p3xFlagcmv7.1 (Sigma). 
Prior to primer generation, the sequence of the fragments of PMCA2b cDNA 
encoding the relevant regions of the PMCA2b protein were analysed for restriction 
site mapping. Primers for PCR reactions were designed containing appropriate 
restriction enzymes for cloning, not found within the fragment of PMCA2b cDNA to 
be amplified. 
The same strategy was used to generate Flag-tagged PMCA1 truncated proteins 
using human PMCA1 cDNA (gene accession number: NM_001682). 
The cloning of an expression plasmid encoding Flag-tagged PMCA4b(428-651) 
including the domain of PMCA4 responsible for the interaction with calcineurin A 
has been previously reported (Buch et al., 2005).  
An overview of the Flag-tagged PMCA truncated proteins used in this study is 
shown in Fig. 3.3.1. 
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Fig. 3.3.1 Schematic overview of the constructs used for determination of the calcineurin 
interaction domain of PMCA2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 713.3.1a(i) Construction of p3xFlag-PMCA2b(1143-1243) plasmid 
To generate construct p3xFlag-PMCA2b(1143-1243) the fragment encoding amino 
acids 1143-1243 of human PMCA2b (numbering according to gene bank 
accession number: NM_001683 ) was amplified by PCR following the standard 
conditions described in section 2.2.1 and using primers;  
sense 5’-TCTTCCCAAgCTTgTCgTgAAggCgTTCCgTAg-3’ and  
antisense 5’-CTTCgCggATCCTCAAAgCgACgTCTCCAggCTgT-3’.  
The optimum annealing temperature for both primers was 64°C.  
The PCR product was digested with restriction enzymes EcoRI and BamHI, and 
cloned into the EcoRI-BamHI sites of plasmid p3xFlag-cmv7.1 (Fig. 3.3.2).  
 
 
 
Fig. 3.3.2   Schematic diagram for the cloning strategy of p3xflag-PMCA2b(1143-1243). 
 
 
 
 
 
 
 
 
 72To confirm the successful generation of the recombinant expression vector 
p3xFlag-PMCA2b(1143-1243), the plasmid was digested with restriction enzymes 
EcoRI and BamHI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (300bp) and plasmid (4700bp) 
as expected (Fig. 3.3.3). 
 
 
 
Fig. 3.3.3    Agarose gel electrophoresis of restriction enzyme digested p3xFlag-PMCA2(1143-
1243). Digestion released a fragment of DNA 300bp in size relating to amino acids 1143-1243 of 
human PMCA2 and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1.  
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 733.3.1a(ii) Construction of p3xFlag-PMCA2b(462-684) plasmid 
To generate construct p3xFlag-PMCA2b(462-684) the fragment encoding amino 
acids 462-684 of human PMCA2b (numbering according to gene bank accession 
number: NM_001683) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’-TCTTCCggAATTCTgCCGTCACCATCTCgTTgg-3’ and  
antisense 5’-CTTCgCggATCCTCACTCCgggCTgCTggggAAgTCg-3’.  
The optimum annealing temperature for both primers was 62°C. 
The PCR product was digested with restriction enzymes EcoRI and BamHI, and 
cloned into the EcoRI-BamHI sites of plasmid p3xFlagcmv7.1 (Fig. 3.3.4).  
 
 
 
Fig. 3.3.4  Schematic diagram for the cloning strategy of p3xflag-PMCA2b(462-684). 
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p3xFlag-PMCA2b(462-684), the plasmid was digested with restriction enzymes 
EcoRI and BamHI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (666bp) and plasmid (4700bp) 
as expected (Fig. 3.3.5). 
 
 
 
Fig. 3.3.5 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-PMCA2(462-684). 
Digestion released a fragment of DNA 666bp in size relating to amino acids 462-684 of human 
PMCA2 and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1 
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 753.3.1a(iii) Construction of p3xFlag-PMCA2b(535-609) 
To generate construct p3xFlag-PMCA2b(535-609) the fragment encoding amino 
acids 535-609 of human PMCA2b (numbering according to gene bank accession 
number: NM_001683) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’-TCTTCCCAAgCTATggAgCTgCTgATCAATgCC-3’and  
antisense 5’-CTTCgCggATCCTCACATggACTTgCgCACggAgTTg-3’.  
The optimum annealing temperature for both primers was 62°C. 
The PCR product was digested with restriction enzymes HindIII and BamHI, and 
cloned into the HindIII-BamHI sites of plasmid p3xFlagcmv7.1 (Fig. 3.3.6).  
 
 
 
Fig. 3.3.6  Schematic diagram for the cloning strategy of p3xflag-PMCA2b(535-609). 
 
 
 
 
 
 
 76To confirm the successful generation of the recombinant expression vector 
p3xFlag-PMCA2(535-609), the plasmid was digested with restriction enzymes 
HindIII and BamHI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (222bp) and plasmid (4700bp) 
as expected (Fig. 3.3.7). 
 
 
 
Fig. 3.3.7 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-PMCA2(535-609). 
Digestion released a fragment of DNA 222bp in size relating to amino acids 535-609 of human 
PMCA2 and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1 
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 773.3.1a(iv) Construction of p3xFlag-PMCA1b(511-585) 
To generate construct p3xFlag-PMCA1b(511-585) the fragment encoding amino 
acids 511-585 of human PMCA1b (numbering according to gene bank accession 
number: NM_001682) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’-TCTTCCggAATTCTTTgTCCTATCTTgTAACAggAA-3’and  
antisense 5’-CTTCgCggATCCTCACATggACTTCCTAACAgAATTG-3’.  
The optimum annealing temperature for both primers was 56°C. 
The PCR product was digested with restriction enzymes EcoRI and BamHI, and 
cloned into the EcoRI-BamHI sites of plasmid p3xFlagcmv7.1 (Fig. 3.3.8).  
 
 
 
Fig.3.3.8 Schematic diagram for the cloning strategy of p3xflag-PMCA1b(511-585). 
 
 
 
 
 
 
 
 78To confirm the successful generation of the recombinant expression vector 
p3xFlag-PMCA1(511-585), the plasmid was digested with restriction enzymes 
EcoRI and BamHI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (222bp) and plasmid (4700bp) 
as expected (Fig.3.3.9). 
 
 
 
Fig. 3.3.9 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-PMCA1(511-585). 
Digestion released a fragment of DNA 222bp in size relating to amino acids 511-585 of human 
PMCA1 and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1. 
 
3.3.2  Analysis of the interaction between calcineurin and recombinant Flag-
tagged PMCA2 truncated proteins 
Flag-tagged fusion proteins containing the amino acid regions 462-684, or 1143-
1243 of PMCA2b were used to investigate if the region 462-684 of PMCA2 may 
interact with calcineurin. Plasmids p3xFlag-PMCA2b(462-684) or p3xFlag-
PMCA2b(1143-1243) were transfected into HEK293 cells. Protein lysates of 
transfected cells were incubated with commercially available calcineurin (40 nM 
final concentration) (Sigma), immunoprecipitated with an anti-calcineurin A 
monoclonal antibody and, subsequently, immunoprecipitated proteins were 
detected by western blot using an anti-Flag monoclonal antibody (Sigma). Flag-
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 79PMCA2b(462-684) co-precipitated with calcineurin (Fig. 3.3.10, upper panel) 
whereas no precipitation was observed for Flag-PMCA2b(1143-1243) (Fig. 3.3.10, 
upper panel) demonstrating the selectivity of the interaction. HEK293 cells 
transfected with the vector p3xFlag-PMCA4b(428-651), encoding the region of 
PMCA4b reported to interact with calcineurin, were used as a positive control (Fig. 
3.3.10,upper panel). These results demonstrated that the region 462-684 of the 
catalytic, big intracellular loop of human PMCA2b is involved in the interaction with 
calcineurin A. 
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Fig. 3.3.10 Amino acid region 462-684 of human PMCA2b interacts with calcineurin A.  Western 
blot and Immunoprecipitation analysis of the interaction between calcineurin A and Flag-tagged 
proteins described in chapter 3 section 3.3. Amino acid region 462-684 of PMCA2 specifically 
interacts with calcineurin A. A representative result from three independent experiments is shown. 
 
Dr. Armesilla’s groups previous data has shown that the region 501-575 (located 
within the interaction domain of PMCA4b, region 428-651) is essential for the 
interaction of this protein with calcineurin A (Buch et al., 2005). Therefore, we next 
tested the ability of the equivalent region of PMCA2b (fragment 535-609) to 
interact with calcineurin A. Following the same strategy as described above, we 
determined that Flag-PMCA2b(535-609) co-precipitated with calcineurin A (Fig. 
3.3.11, upper panel), however precipitation occurred to a lesser degree than that 
 80observed for the whole interaction domain (462-684), suggesting that the region 
535-609 of PMCA2b interacts with calcineurin, although some adjacent sequences 
might be essential for a full interaction. To confirm the lack of interaction between 
PMCA1 and calcineurin A we generated an expression vector encoding Flag-
PMCA1b(511-585), a Flag-tagged fusion protein containing the region of human 
PMCA1b equivalent to the region 535-609 of PMCA2b. Precipitation of calcineurin 
A failed to co-precipitate Flag-PMCA1b(511-585) (Fig. 3.3.11, upper panel) 
confirming the lack of interaction observed between endogenous PMCA1 and 
calcineurin.  
Western blot, with a monoclonal antibody raised against the Flag epitope, of the 
protein extracts prior to immunoprecipitation showed similar expression of the 
Flag-tagged fusion proteins in the different transfections (Fig 3.3.10 and Fig. 
3.3.11, lower panels). Poor expression was ruled out for the lack of interaction as 
the Flag-tagged proteins were expressed at equivalent levels. 
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Fig. 3.3.11    The region 535-609 interacts with calcineurin. Immunoprecipitation and western blot 
analysis of Flag recombinant protein containing the region 535-609 of human PMCA2 showed a 
weak interaction between this domain of PMCA2 and calcineurin A. However the Flag-tagged 
protein containing the equivalent region of PMCA1 did not interact at all with calcineurin A. A 
representative result from three independent experiments is shown. 
 
 813.4  Functional analysis of the interaction between PMCA2 and calcineurin 
To determine the functionality of the interaction between PMCA2 and calcineurin, 
an NFAT-dependent luciferase reporter assay was performed as an indicator of 
the effect of PMCA2 overexpression on calcineurin activity. Calcineurin 
dephosphorylates NFAT allowing it to translocate to the nucleus of the cells and 
activate NFAT-dependent genes. To monitor the activity of the calcineurin/NFAT 
pathway we transfected HEK293 cells with a pNFAT-TA-luc plasmid (Clontech) 
which when activated by NFAT promotes the expression of luciferase. A luciferase 
substrate is then added to the lysed cells and the relative luciferase units (RLU) 
are a direct representation of NFAT activation and consequently calcineurin 
activity. 
Plasmids pcDNA3-PMCA2, pcDNA3-PMCA1 or pcDNA3-empty were transfected 
into HEK293 cells along with pNFAT-luc. Cells were stimulated with PMA and 
calcium ionophore for 16 hours to activate the calcineurin/NFAT pathway. Cell 
lysates of the transfected cells were incubated with luciferase substrate and the 
RLU was measured for each experimental condition.  
Ectopic expression of PMCA2 in HEK293 cells resulted in a 32% reduction in 
NFAT-dependent luciferase (and therefore calcineurin/NFAT) activity. However, 
the transfection of an expression plasmid encoding PMCA1 did not reduce NFAT-
dependent luciferase production, confirming the lack of an interaction between 
PMCA1 and calcineurin observed previously (fig. 3.4.1). 
These results indicate that PMCA2 inhibits the calcineurin/NFAT pathway in 
mammalian cells when overexpressed and that this interaction is specific to 
PMCA2, as PMCA1 overexpression had no effect on calcineurin activity. 
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Fig. 3.4.1 NFAT transcriptional activity is significantly inhibited by PMCA2. PMCA2 inhibits the 
activation of an NFAT-dependent luciferase reporter vector in response to PMA plus Calcium 
ionophore (Io) A23187 treatment of cells. HEK293 cells were co-transfected with 10μg of pcDNA3-
hPMCA2b or control vector pcDNA3, and 5μg of the NFAT –dependent luciferase reporter vector 
pNFAT-TA-Luc. PMA (20ng/ml) plus Io (1μM) was used to stimulate the cells for 16h. Induction 
after PMA/Io stimulation of reporter vector luciferase activity in the presence of co-transfected 
control plasmid pcDNA3 was taken as reference (100%), this control experiment was perfomed 
independently for each of the different conditions but combined to allow the data presentation in 
one graph. A significant reduction (32% inhibition) of luciferase activity was observed after co-
expression of human PMCA2b. ∗, statistically significant (p≤0.05, according to an unpaired 
Student’s t test) when compared to NFAT-luc/pcDNA3-empty controls. Means ± S.E. of six 
independent experiments are shown. 
 
3.5 Disruption of the interaction between endogenous PMCA2 and 
calcineurin by Flag-PMCA2(462-684) activates the calcineurin/NFAT 
pathway. 
Region 462-684 of PMCA2 encompasses the interaction domain of PMCA2 with 
calcineurin A. We hypothesised that by ectopically overexpressing this region in 
HEK293 cells the interaction between endogenous PMCA2 and calcineurin A 
could be disrupted. To demonstrate this disruption HEK293 cells were co-
transfected with pcDNA3, pcDNA3-PMCA2 or pcDNA3-PMCA2(462-684) and the 
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 83NFAT-dependent luciferase
 reporter vector pNFAT-TA-Luc (Clontech). Cells were 
stimulated with PMA/Io for 16 hours induce
 calcineurin A activation and 
consequent NFAT transcriptional activity. Cell lysates were incubated with 
luciferase substrate and the RLU for each experimental condition was recorded.  
A significant increase (55%) was detected in the PMCA/Io-dependent luciferase 
activity of samples expressing F-PMCA2(462-684) protein (Fig. 3.5.1). Upon the 
addition of pcDNA2-PMCA2b the effect caused by F-PMCA2b(462-684) on the 
activation of the luciferase reporter vector was reversed.  A control experiment 
was performed with pcDNA3-empty and pNFAT-luc, this was used as the value for 
100% activation of NFAT. 
These results suggest that F-PMCA2b(462-684) significantly disrupts the 
interaction between endogenous PMCA2 and calcineurin A in mammalian cells. 
This disruption can be overcome by expressing an excess of the whole PMCA2 
molecule. Disruption of the interaction PMCA2/calcineurin results in a significant 
increment in the activity of the calcineurin/NFAT pathway, confirming our 
hypothesis of a role for the interaction PMCA/calcineurin as an endogenous 
inhibitor of the calcineurin/NFAT pathway.
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Fig. 3.5.1 Ectopic expression of F-PMCA2(462-684) significantly activates NFAT transcriptional 
activity and further introduction of PMCA2 reverses this effect. F-PMCA2(462-684) activates the 
activity of an NFAT-dependent luciferase reporter vector in response to PMA plus calcium 
ionophore (Io) A23187. 5μg of pF-PMCA2(462-684) or control vector pcDNA3-empty, 2.5μg of 
pcDNA3-PMCA2 and 7.5μg of the NFAT-dependent luciferase reporter vector pNFAT-TA-Luc were 
co-transfected in HEK293 cells. Cells were stimulated with PMA (20ng/mL) plus Io (1μM) for 16 h. 
Induction after PMA/Io stimulation of reporter vector luciferase activity in the presence of co-
transfected control plasmid pcDNA3-empty was taken as reference, this control experiment was 
perfomed independently for each of the different conditions but combined to allow the data 
presentation in one graph. Co-expression of F-PMCA2(462-684) resulted in a significant increase 
(55%) of luciferase induction. Co-expression of F-PMCA2(462-684) and human PMCA2 resulted in 
a significant reversal (70%) of this effect. *, statistically significant (p ≤ 0.05, according to an 
unpaired Student’s T-test) when compared to NFAT-luc/pcDNA3-empty controls. Mean ± S.E. of 
six independent experiments are shown. 
 
 853.6 PMCA-calcineurin interaction in primary endothelial cells, HUVEC. 
It has been previously reported that the calcineurin/NFAT pathway plays a major 
role in the progression of angiogenesis in response to VEGF stimulation of 
endothelial cells. The expression of PMCAs in endothelial cells prompted us to 
analyse the possibility that endogenous PMCA and calcineurin interact in 
endothelial cells. To test this hypothesis, Human Umbilical vein endothelial cells 
(HUVEC) were used as a model for primary endothelial cells. 
To determine any interaction between PMCA and calcineurin in HUVEC cells, 
protein extracts were immunoprecipitated with a monoclonal anti-calcineurin A 
antibody (Sigma). Precipitated proteins were probed by western blot using 
isoform-specific anti-PMCA antibodies (Swant).  
A very faint, reproducible band corresponding to PMCA1 was detected in samples 
probed with an anti-PMCA1 antibody (Fig. 3.6.1, lower panel). This suggests a 
very weak interaction between endogenous calcineurin A and human PMCA1 in 
HUVEC cells. High levels of co-precipitated PMCA2 and 4 were revealed by 
performing a western blot with anti-PMCA2 and –PMCA4 antibodies respectively 
(Fig. 3.6.1, top and middle panels). This data suggests a strong interaction 
between both human PMCA2 and 4 and endogenous calcineurin A in HUVEC 
cells. Immunoprecipitations carried out with the 5F10 anti-PMCA monoclonal 
antibody were performed as a control and demonstrated high expression levels of 
PMCA1, 2 and 4 isoforms in HUVEC cells (Fig. 3.6.1), indicating that low 
expression levels of PMCA1 or low affinity of the antibody were not the cause of 
the weak band detected.  
Confirmation on the selectivity of the interactions was determined by 
immunoprecipitations carried out with an irrelevant antibody (anti-Luciferase) 
which precipitated no protein in all cases (Fig. 3.6.1).  
To summarise these results show that PMCA interacts with calcineurin in HUVEC 
endothelial cells and suggests that the strongest interactions are detected 
between PMCA2 or 4 and calcineurin. 
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Fig. 3.6.1 Endogenous PMCA and calcineurin interact in HUVEC endothelial cells. Calcineurin A 
and PMCA 1, 2 and 4 co-precipitation demonstrates a strong interaction between calcineurin A and 
PMCA2 or 4. (5F10) anti-PMCA monoclonal antibody, (α-luc) anti-luciferase antibody and (α-cal) 
anti-calcineurin A monoclonal antibody. Western blots of immunoprecipitated proteins were probed 
with antibodies specific for PMCA1, PMCA2 or PMCA4 (Swant) to detect PMCA1 (WB: PMCA1), 
PMCA2 (WB: PMCA2) and (WB: PMCA4) respectively. A representative result from three 
independent experiments is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 873.7 Discussion 
Previous findings by Dr Armesilla’s group have shown that PMCA interacts with 
calcineurin and inhibits its activity and subsequent signalling pathways (Buch et 
al., 2005). It was the aim of this research to further define this interaction in an 
isoform- and tissue-specific manner. 
 
This investigation has demonstrated that endogenous PMCA and calcineurin 
interact in an isoform-specific manner in MCF-7 breast adenocarcinoma cells and 
primary endothelial cells. The strongest interaction was detected between PMCA2 
and calcineurin A and the calcineurin/NFAT pathway was inhibited by 
overexpression of PMCA2. Overexpression of the flag-tagged PMCA2 interaction 
domain, amino acids (462-684), resulted in the functional disruption of the 
interaction between endogenous PMCA2 and calcineurin. 
 
This investigation also found that PMCA2b, 1b and 4b proteins are expressed in 
endothelial and breast cancer cells. The finding that PMCA2 was the important 
isoform for the interaction with calcineurin in endothelial and breast cancer cells is 
interesting as PMCA2 has been described as the isoform of PMCA with the 
highest calmodulin affinity (Elwess et al., 1997), it has been shown to be 2-3 times 
more active than PMCA1 and 4, the ubiquitously expressed PMCA isoforms (Hill 
et al., 2006) and maintains high basal activity in the absence of activators (Hilfiker 
et al., 1994). 
 
3.7.1 PMCA2/calcineurin  interaction and mammary tissue 
PMCA2 has been implicated to play a major role in mammary gland physiology. 
PMCA2b has been found to be highly expressed in lactating mammary tissues 
(Reinhardt et al., 2000) and mice homozygous for a null-mutation of the pmca2 
gene produced milk with 60% less calcium than wild type animals (Reinhardt et al., 
2004). It is possible that PMCA2 is localised to certain cells within that lactating 
mammary gland where it may also play an essential role in inhibiting calcineurin-
mediated apoptosis by sequestering and inhibiting calcineurin activity allowing 
these cells to evade apoptosis and continue to produce high levels of calcium 
which would normally trigger apoptosis. 
 883.7.2 PMCA2/calcineurin  interaction and cancer 
Elements of signal transduction pathways are often deregulated in cancer cells 
contributing to a malignant phenotype. There have been a number of reports 
where calcineurin inhibitors used during immunosuppression have resulted in 
increased risk of cancer development (reviewed in Weischer et al., 2007), 
indicating that calcineurin-mediated apoptosis may be an important mechanism in 
reducing cancer development. In support of this theory Rivera et al. (2005) have 
demonstrated that the p53 tumour suppressor plays an important role in the 
activation of calcineurin-mediated apoptosis, demonstrating the importance of 
calcineurin regulation in cancer progression. 
PMCA2 expression has been found to be up-regulated in breast cancer cell (Lee 
et al., 2005). These findings suggest that deregulation of PMCA might contribute 
to breast tumorigenesis. The work conducted during this project has demonstrated 
that PMCA2 inhibits the activity of calcineurin and the subsequent 
calcineurin/NFAT pathway. Increased PMCA2 expression in breast cancer cells 
would therefore be expected to inhibit the calcineurin/NFAT pathway and 
subsequent calcineurin-mediated apoptosis (Asai et al., 1999). PMCA2-mediated 
down-regulation of calcineurin activity might result in inhibition of apoptosis and 
promotion of tumorigenesis in cancer cells. In agreement with this hypothesis, 
Padma, et al. (2005) have shown that calcineurin activity is down-regulated in 
cervical carcinoma. It would be interesting to analyse the level of PMCA2 
expression in these cells and determine if it regulates calcineurin activity and 
apoptosis in cervical carcinomas. Also PMCA2 expression is elevated in 
neuroblastoma cells (Usachev et al., 2001) determination of the effect of this on 
calcineurin activity would be an interesting avenue to pursue. 
Over-expression of other PMCA isoforms has also been recorded in certain 
cancers. Aung et al. (2007) and Ribiczey et al. (2007) have found that PMCA4 
may play a role in colon cancer and gastric cancers, indicating that the isoform of 
PMCA which is up-regulated is dependent on the cancerous cell type.  
 
 
 
 
 
 893.7.3 PMCA2/calcineurin  interaction and hair cells 
The finding that PMCA2 interacts with and inhibits calcineurin activity and that this 
may hypothetically regulate calcineurin-mediated apoptosis might have some 
relevance to the hearing and balance deficits observed in PMCA2 knockout mice 
models (Kozel et al., 1998).  
It has been observed that PMCA2 is expressed at high levels in the outer hair cells 
of the cochlea (Furuta et al., 1998). Dodson et al. (2001) have demonstrated that 
in mice with mutated PMCA2 function (deafwaddler) apoptotic hair cell death is 
increased. Hypothetically the lack of functional PMCA2 in the deafwaddler mouse 
might lead to an increase in calcineurin-mediated apoptosis in outer hair cells 
resulting from increased calcineurin activity. Vincente-Torres and Schacht (2006) 
have demonstrated that increased activity of calcineurin promotes cochlear 
acoustic injury by outer hair cell death. To support this hypothesis Minami et al. 
(2004) and Uemaetomari et al. (2005) in two separate experiments have shown 
that calcineurin inhibitors, cyclosporine A and FK506, can decrease noise-induced 
hearing loss. All this evidence suggests that the PMCA and calcineurin interaction 
may play a major role in the regulation of apoptosis in hair cells. Potentially 
PMCA2 mutations and their effect on calcineurin-mediated apoptosis might be 
important in some hearing disorders displayed in humans. Evidence to support this 
has been provided by Schultz et al. (2005) where they demonstrated that certain 
mutations in PMCA2 can result in modifications of human hearing-loss 
phenotypes, specifically noise induced sensorineural hearing loss.  
 
3.7.4 PMCA2/calcineurin  interaction and neuronal degeneration 
As well as being implicated in hearing loss and cancer the PMCA2-calcineurin 
interaction may also regulate apoptosis in neuronal cells. PMCA2 is involved in 
neuronal development and is highly expressed in fully differentiated neurons 
(Guerini et al., 1999). In diseases such as multiple sclerosis, where neuronal 
damage is a key feature, the expression of PMCA2 has been shown to be down-
regulated (Nicot et al., 2003) potentially increasing the rate of calcineurin-mediated 
apoptosis in neuronal cells and augmenting the disease.  
As well as having an involvement in neuronal disease the PMCA-calcineurin 
interaction may be relevant in spinal cord injuries involving ischemia of neuronal 
cells. Certain areas of the brain more susceptible to ischemia also contain 
 90relatively high concentration of calcineurin (Goto et al., 1986). Asai et al. (1999) 
suggest that it is this high level of calcineurin that predisposes these cells to 
apoptosis.  
Preliminary research in rat neurons, used for ischemia therapy, by Castilho et al. 
(2000) has demonstrated that treatment of grafted neurons with cyclosporine A 
increased their survival, possibly due to the inhibition of calcineurin-mediated 
apoptosis (Canellada et al., 2006). This has also been shown to be the case in 
human neurons where treatment with cyclosporin A protected neurons against 
ischemia induced programmed cell death, implicating calcineurin-mediated 
apoptosis (Sheehan et al., 2006). 
This is encouraging evidence for the potential of PMCA2 overexpression in 
neurons as a specific therapy for neuronal degeneration seen in spinal cord 
injuries and disease, by the inhibition of calcineurin-mediated apoptosis.  
 
3.7.5 PMCA2/calcineurin  interaction  and pathological cardiac hypertrophy 
The regulation of calcineurin by PMCA2 may also have implications in pathological 
cardiac hypertrophy. The calcineurin/NFAT pathway is known as a key signal 
transduction pathway in mediating cardiac hypertrophy (Molkentin et al., 1998). 
Although the predominant forms of PMCAs in the heart are isoforms 1 and 4, 
PMCA2 has also been shown to be expressed to a lesser degree (Guerini et al., 
1999) and since this isoform is 2-3 times more active and with a higher basal 
activity (Hill et al., 2006 and Hilfiker et al., 1994), its effects may be more wide-
spread than that of the ubiquitously expressed PMCA isoforms. Zwadlo et al. 
(2005) have shown that PMCA2 gene expression is elevated in a spontaneous 
hypertensive rat model (SHR), supporting the hypothesis that PMCA2 may inhibit 
calcineurin and calcineurin-mediated cell cycle regulation (reviewed in Vega et al., 
2003) in aberrant cardiac cells, leading to hypertension and hypertrophy. 
Cyclosporine A treatment of cardiac hypertrophy in mouse and rat models often 
resulted in inhibition or complete reversal of the effects, however there were 
obvious adverse side-effects caused by the wide-ranging effects of cyclosporine A. 
Research into specific calcineurin inhibitors is important in this field, as 
cardiomyopathy and heart failure often occur from sustained hypertrophy, (Schulz 
and Yutzey, 2004). 
 
 913.7.6 PMCA2/calcineurin  interaction and Diabetes 
PMCA2 has been shown to be expressed in pancreatic β cells (Kamagate et al., 
2000). The expression level of PMCA2 in diabetic β cells has yet to be 
established, but theoretically if the level of PMCA2 were to be increased in the 
diseased state, calcineurin-mediated cell cycle regulation would halt resulting in a 
lack of β cell proliferation and growth. In support of this hypothesis, upon glucose 
stimulation in the healthy β cell, a switch occurs from the low efficiency PMCA2 to 
a higher affinity calcium pump (Herchuelz et al., 2007). It is perhaps the case that 
this switch does not occur in diabetic β cells resulting in increased calcineurin 
inhibition by PMCA2. Sustained high glucose levels have been found to inhibit the 
expression and activity of PMCA2 (Reviewed in Gagliardino et al., 1994) in which 
case calcineurin would be released from inhibition and may perhaps instigate 
expression of genes related to calcineurin-mediated apoptosis triggered by 
different signals than those that promote cell cycle progression.  
 
3.7.7 PMCA2/calcineurin  interaction and Angiogenesis 
Armesilla et al. (1999) have demonstrated that upon VEGF stimulation of primary 
endothelial cells, NFAT, the primary substrate of calcineurin, is dephosphorylated 
and may play a role in the expression of tissue factor, an important glycoprotein 
involved in the regulation of endothelial cell sprouting during angiogenesis (Senger 
1996). Further support for the essential role of calcineurin in angiogenesis has 
been demonstrated by Hernandez et al. (2001). They have shown that VEGF-
mediated angiogenesis is inhibited by the specific calcineurin inhibitor, 
cyclosporine A. Graef et al. (2001) have shown that a lack of calcineurin/NFAT 
signalling can result in the inhibition of vessel growth and that vessels tend to grow 
into regions with high NFAT expression.  
This project has demonstrated that PMCA2 is expressed in endothelial cells and 
strongly interacts with calcineurin. It is possible to consider the overexpression of 
PMCA2 as a way to regulate vessel growth as a therapy in conditions where 
aberrant angiogenesis occurs, such as diabetic retinopathy and cancer.  
Conversely by using a small interacting peptide, such as the pFlag-PMCA2(462-
684) created during this project, the inhibitory interaction between PMCA2 and 
calcineurin could be overcome resulting in increased calcineurin/NFAT signaling 
 92and angiogenesis, as a therapy for prevention of conditions such as 
atherosclerosis or for increasing wound healing capabilities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 933.8 Conclusion 
In conclusion, our results demonstrate that the interaction between endogenous 
PMCA and calcineurin is isoform-specific in MCF-7 adenocarcinoma cells and 
endothelial cells suggesting that this interaction might play an important role in the 
regulation of many important physiological and pathological conditions. 
This work has also demonstrated that PMCA2 can inhibit the calcineurin/NFAT 
pathway and that this inhibition can be disrupted by the overexpression of the 
small interacting protein pFlag-PMCA2(462-684) which expresses the region of 
PMCA2 primarily involved in the interaction with calcineurin. This discovery sheds 
new light on PMCA as a regulator of signal transduction pathways and may 
provide potential avenues for the development of effective inhibitors and activators 
of the calcineurin/NFAT pathway that may have fewer side-effects than treatments 
currently available, due to their endogenous and specific nature.  
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4. CHAPTER FOUR RESULTS 
 
PMCA AS AN INHIBITOR OF THE NITRIC OXIDE SIGNAL TRANSDUCTION 
PATHWAY. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 954.1 Introduction 
Schuh et al. (2001) have recently demonstrated that PMCA4 interacts with 
neuronal NOS, nNOS, in mammalian cells and this interaction has an inhibitory 
effect on the production of NO by nNOS in cardiac cells (Oceandy et al., 2007). In 
this thesis the interaction between PMCA isoforms and the endothelial isoform of 
NOS, eNOS, has been investigated in endothelial cells to extend the current 
knowledge on PMCA interactions with NOS isoforms. 
 
4.2 Analysis of the interaction PMCA-eNOS in HUVEC primary endothelial 
cells 
To analyse the interaction between endogenous PMCA 1, 2 and 4 and eNOS in 
endothelial cell line EAhy926 and HUVEC cells, 5F10 anti-PMCA monoclonal 
antibody (abcam) was used to immunoprecipitate protein extracts isolated from 
EAhy926 and HUVEC cells. A western blot was then performed on 
immunoprecipitated proteins using a rabbit anti-eNOS antibody (Sigma) (Fig. 
4.2.1, A). A strong and reproducible band corresponding to eNOS was visible in 
western blots for both EAhy926 and HUVEC cells indicating that PMCA and eNOS 
interact strongly in both endothelial cells types. 
The 5F10 monoclonal antibody recognizes all PMCA isoforms. As a first step to 
evaluate the isoform/s of PMCA involved in the interaction with eNOS, the 
expression of PMCA isoforms in HUVEC primary cells was assessed. For this 
purpose 5F10 anti-PMCA monoclonal antibody was used to immunoprecipitate 
protein extracts from HUVEC cells. A western blot was then performed on 
immunoprecipitated proteins using isoform-specific anti-PMCA antibodies (Swant). 
Strong and reproducible bands for PMCA isoforms 1, 2 and 4 were visible in 
western blots indicating that they are expressed in HUVEC cells (Fig. 4.2.1, B). 
The determination of the isoform involved in the interaction of PMCA with eNOS 
was performed using isoform-specific PMCA antibodies (Swant) against PMCA1, 2 
or 4, to immunoprecitate protein extracts from HUVEC cells. Western blot was 
then performed with a monoclonal anti-eNOS antibody (Zymed). 
Reproducible bands for each PMCA isoform were visible, however, the bands for 
PMCA 1 and 4 were weak compared to the band for PMCA2 which was stronger 
(Fig. 4.2.1, C). 
 96The selectivity of the interactions was confirmed by performing control 
immunoprecipitations with an irrelevant antibody (anti-luciferase) (Promega) in 
which no protein was precipitated (Fig. 4.2.1, C). 
These results demonstrate the interaction between endogenous PMCAs and 
eNOS in endothelial cells. They suggest that PMCA2 is the predominant isoform 
interacting with eNOS, although a very weak interaction is also visible between 
eNOS and PMCAs 1 and 4. 
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Fig. 4.2.1  Endogenous PMCA and eNOS interact in human endothelial cells. A, PMCA and eNOS 
co-precipitate in endothelial cells. Primary HUVEC endothelial cells (right panel) or the HUVEC-
derived endothelial cell line EAhy926 (left panel) protein lysates were incubated with an anti-PMCA 
monoclonal antibody (5F10), or an irrelevant antibody raised against firefly luciferase (α-Luc), and 
Western blot of the immunoprecipitated proteins was performed with an anti-eNOS rabbit 
polyclonal antibody. B, Isoforms 1, 2 and 4 of PMCA are expressed in HUVEC cells. HUVEC cell 
protein lysates were precipitated with an anti-PMCA monoclonal antibody (5F10), or an irrelevant 
antibody raised against firefly luciferase (α-Luc). Western blot of the precipitated proteins was 
performed with rabbit polyclonal antibodies specific for PMCA isoforms 1, 2, or 4 (Swant). PMCA 
isoforms 1, 2, and 4 were expressed in HUVEC cells. C, The main isoform interacting with eNOS in 
endothelial cells is PMCA2. Protein extracts isolated from HUVEC cells were immunoprecipitated 
with polyclonal antibodies recognising specifically the isoforms 1, 2, or 4 of PMCA (Swant). 
Immunoprecipitated proteins were subjected to western blot analysis with an anti-eNOS mouse 
antibody (Zymed). Endogenous PMCA1 and 4 co-precipitated weakly with eNOS, whereas, 
PMCA2 and eNOS co-precipitated strongly, suggesting that in endothelial cells PMCA2 is the 
major isoform interacting with eNOS. An irrelevant antibody against firefly luciferase (α-Luc) was 
used during immunoprecipitation as a negative control and an antibody against eNOS (α-eNOS) 
was used as a positive control. A representative result from three independent experiments is 
shown. 
 98As PMCA2 seems to be the predominant PMCA isoform interacting with eNOS the 
project focused on the interaction between these two proteins from this point 
onwards.  
 
4.3 Analysis of the ectopic interaction between PMCA2 and eNOS in 
mammalian cells 
In order to further confirm the interaction of PMCA2 with eNOS, human PMCA2 
and eNOS were ectopically expressed in mammalian HEK293 cells. 
To analyse the interaction between ectopic PMCA2 and eNOS in HEK293 cells, 
pcDNA3-PMCA2 (encoding human PMCA2) and pcDNA3-eNOSHumanA 
(encoding human eNOS) plasmids were transfected into HEK293 cells. Protein 
lysates of transfected cells were immunoprecipitated with 5F10, anti-PMCA 
monoclonal antibody. A western blot was then performed on the 
immunoprecipitated proteins using a rabbit anti-eNOS antibody (Sigma). As a 
negative control HEK293 cells were also transfected with pcDNA3-empty and 
pcDNA3-eNOS plasmids in the absence of ectopic pcDNA3-PMCA2. 
A strong, reproducible band representing ectopic eNOS was only detected in 
samples expressing both ectopic PMCA2 and eNOS (Fig. 4.3.1, upper panel). In 
samples expressing only eNOS no band was visible, as expected. Ectopic 
expression of PMCA2 had no effect on the expression of the recombinant eNOS 
protein (Fig. 4.3.1, lower panel). The selectivity of the interaction was confirmed by 
performing control immunoprecipitations using an irrelevant antibody (anti-
luciferase) (Promega) in which no protein was precipitated (Fig. 4.3.1). 
To summarise, these results demonstrate that ectopically expressed PMCA2 and 
eNOS interact strongly and specifically in HEK293 mammalian cells. 
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Fig. 4.3.1 Ectopically expressed PMCA2b and eNOS interact in HEK293 cells. Co-transfection of 
HEK 293 cells with expression vector pcDNA3-eNOS (encoding human eNOS) together with either 
pcDNA3-empty plasmid (negative control) or pcDNA3-hPMCA2b (encoding human PMCA2b). An 
antibody against PMCA (5F10) or an irrelevant antibody raised against firefly luciferase (α-Luc) 
were used to immunoprecipitate protein lysates from transfected cells. An anti-eNOS rabbit 
antibody (Sigma) was used during Western blot analysis to detect immunoprecipitated proteins or 
expression levels of eNOS. A representative result from three independent experiments is shown. 
  
4.4 Analysis of the interaction between eNOS and recombinant Flag-tagged 
PMCA2 truncated proteins. 
As shown in Chapter three region 462-684 of PMCA2 interactys with calcineurin, a 
calcium/calmodulin-dependent protein. This highlighted the possibility that this 
domain of PMCA2 may also interact with eNOS, as it too is regulated by 
calcium/calmodulin. Another domain of PMCA2 potentially implicated in the 
interaction with eNOS is the region 1143-1243, corresponding to the C-terminal tail 
of PMCA2. The regions of PMCA1 and 4 equivalent to this have been described to 
interact with nNOS in mammalian cells (Schuh et al., 2001). 
 100The involvement of these two domains of PMCA2 in the interaction with eNOS 
was investigated in this work using flag-tagged fusion proteins containing the 
amino acid regions 462-684, or 1143-1243 of PMCA2b to investigate if the region 
462-684 of PMCA2 may interact with eNOS. Plasmids p3xFlag-PMCA2b(462-684) 
or p3xFlag-PMCA2b(1143-1243) were transfected into HEK293 cells. The 
generation of expression plasmids p3xFlag-PMCA2(462-684) and p3xFlag-
PMCA2(1143-1243) have been described previously (section 3.2.1). 
Protein lysates of transfected cells were incubated with commercially available 
recombinant human eNOS (10 μM final concentration) (Sigma), 
immunoprecipitated with an anti-eNOS monoclonal antibody and, subsequently, 
immunoprecipitated proteins were detected by Western blot using an anti-Flag 
monoclonal antibody (Sigma). Flag-PMCA2b(462-684) co-precipitated with eNOS 
(Fig. 4.4.1, upper panel) whereas no precipitation was observed for Flag-
PMCA2b(1143-1243) or the negative control pcDNA3-empty (Fig. 4.4.1, upper 
panel) demonstrating the selectivity of the interaction. Both recombinant proteins 
were expressed at equal levels (Fig. 4.4.1, lower panel). These results 
demonstrate that the region 462-684 of the catalytic, big intracellular loop of 
human PMCA2b is involved in the interaction with eNOS 
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Fig. 4.4.1 eNOS interacts with region 462-684 of PMCA2b. HEK293 cells were transfected with 
Flag-tagged PMCA2(426-684) or PMCA2(1143-1243). As a negative control pF-CMV7.1 empty 
vector (Sigma) (F-empty) was used. Commercial recombinant eNOS (Sigma) (10 µM, final 
concentration) was incubated with protein lysates and precipitated with an anti-eNOS polyclonal 
antibody (Sigma). M2 anti-Flag peroxidase monoclonal antibody (upper panel) was used to detect 
immunoprecipitated proteins during Western blot analysis. Prior to immunoprecipitation expression 
levels were analysed by Western blot using the same antibody (lower panel). The region 426-684 
of PMCA2 was found to specifically interact with eNOS. A representative result from three 
independent experiments is shown. 
 
4.5 Determination of the domain of eNOS interacting with PMCA2 
4.5.1 Generation of the Flag-tagged expression plasmids for identification of the 
eNOS domain interacting with PMCA2 
To further characterize the interaction between PMCA2 and eNOS the domain of 
eNOS interacting with PMCA2 was also defined. Flag-tagged recombinant 
proteins were constructed encoding various small regions of eNOS spanning the 
whole length of the eNOS protein to determine the domain involved in the 
interaction with PMCA2. 
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4.5.1a Cloning strategy 
In order to generate expression vectors encoding Flag-tagged truncated proteins 
of human eNOS, the corresponding fragments of human eNOS cDNA (gene bank 
accession number: NM_000603) were amplified by PCR and cloned into the 
expression vector p3xFlagcmv7.1 (Sigma). The fidelity of the amplified fragment 
was confirmed by sequencing. 
Prior to primer generation, the sequence of the fragments of eNOS cDNA 
encoding the relevant regions of the eNOS protein were analysed for restriction 
site mapping. Primers for PCR reactions were designed containing appropriate 
restriction enzymes for cloning, not found within the fragment of eNOS cDNA to be 
amplified. 
An overview of the Flag-tagged eNOS truncated proteins used in this study is 
shown in Fig. 4.5.1. 
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Fig. 4.5.1 Schematic overview of the constructs used for determination of the PMCA2 interaction 
domain of eNOS. A) Full length eNOS including phosphorylation sites and domains as a reference. 
B) Structure of eNOS flag-tagged fusion proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1044.5.1a(i) Construction of pFlag-eNOS(1-505) plasmid 
To generate construct pFlag-eNOS(1-505) naturally occurring restriction enzyme 
sites HindIII and BglII of human eNOS were utilized. The pcDNA3-eNOSHumanA 
plasmid was digested with restriction enzymes HindIII-BglII and cloned into the 
HindIII-BglII sites of plasmid pFlag-cmv5b (Fig. 4.5.2). 
 
 
 
Fig. 4.5.2 Schematic diagram of the cloning strategy for pflagcmv5b-eNOS (1-505).  
 
 
 
 
 
 
 
 
 
 
 
 
 105To confirm the successful generation of the recombinant expression vector pFlag-
eNOS(1-505), the plasmid was digested with restriction enzymes HindIII-BglII. 
DNA electrophoresis of the digestion reaction in agarose gels showed two DNA 
fragments corresponding to insert (1515bp) and plasmid (4700bp) as expected 
(Fig. 4.5.3) 
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Fig. 4.5.3 Agarose gel electrophoresis of restriction enzyme digested pflagcmv5b-eNOS (1-505). 
Digestion released a fragment of DNA 1515bp in size relating to amino acids 1-505 of human 
eNOS and a larger fragment of 4.7 relating to the expression plasmid pflagcmv5b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1064.5.1a(ii) Construction of p3xFlag-eNOS(193-735) plasmid 
To generate construct p3xFlag-eNOS(193-735) the fragment encoding amino 
acids 193-735 of human eNOS (numbering according to gene bank accession 
number: NM_000603) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’-TCTTCCggAATTCTCTgCAggTgTTCgATgCCCg -3’ and  
antisense 5’- CTTCCCTCTAgATCACTggCgCTTCCAgCTCCg -3’. 
The optimum annealing temperature for both primers was 62°C.  
The PCR product was digested with restriction enzymes EcoRI and XbaI, and 
cloned into the EcoRI-XbaI sites of plasmid p3xflag-cmv7.1 (Fig. 4.5.4).  
 
 
 
Fig. 4.5.4 Schematic diagram of the cloning strategy for p3xFlag-eNOS(193-733) 
 
 
 
 
 
 
 
 107To confirm the successful generation of the recombinant expression vector 
p3xFlag-eNOS(193-735), the plasmid was digested with restriction enzymes 
EcoRI and XbaI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (1626bp) and plasmid 
(4700bp) as expected (Fig. 4.5.5) 
 
 
12216bp 
2036bp 
1636bp 
1018bp 
5066bp 
3054bp 
 
Fig. 4.5.5 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-eNOS(193-733). 
Digestion released a fragment of DNA 1.6kb in size relating to amino acids 193-733 of human 
eNOS and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1.  
 
 
 
 
 
 
 
 
 
 
 
 1084.5.1a(iii) Construction of p3xFlag-eNOS(401-940) plasmid 
To generate construct p3xFlag-eNOS(401-940) the fragment encoding amino 
acids 401-940 of human eNOS (numbering according to gene bank accession 
number: NM_000603) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’-TCTTCCggAATTCTCTgCAggTgTTCgATgCCCg -3’ and  
antisense 5’-CTTCCCTCTAgATCACTggCgCTTCCAgCTCCg -3’. 
 The optimum annealing temperature for both primers was 62°C.  
The PCR product was digested with restriction enzymes EcoRI and XbaI, and 
cloned into the EcoRI-XbaI sites of plasmid p3xflag-cmv7.1 (Fig. 4.5.6). 
 
 
  
Fig. 4.5.6   Schematic diagram of the cloning strategy for p3xflag-eNOS(401-940). 
 
 
 
 
 
 
 
 109To confirm the successful generation of the recombinant expression vector 
p3xFlag-eNOS(401-940), the plasmid was digested with restriction enzymes 
EcoRI and XbaI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (1617bp) and plasmid 
(4700bp) as expected (Fig. 4.5.7) 
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Fig. 4.5.7 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-eNOS(401-940). 
Digestion released a fragment of DNA 1617bp in size relating to amino acids 401-940 of human 
eNOS and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 1104.5.1a(iv) Construction of p3xFlag-eNOS(735-940) plasmid 
To generate construct p3xFlag-eNOS(735-940) the fragment encoding amino 
acids 735-940 of human eNOS (numbering according to gene bank accession 
number: NM_000603) was amplified by PCR following the standard conditions 
described in section 2.2.1 and using primers;  
sense 5’- TCTTCCggAATTCTgAAATCAACgTggCCgTgCT -3’ and  
antisense 5’- CTTCCCTCTAgATCAgTAgTACCggggCTggAgCAg -3’. 
The optimum annealing temperature for both primers was 66°C.  
The PCR product was digested with restriction enzymes EcoRI and XbaI, and 
cloned into the EcoRI-XbaI sites of plasmid p3xflag-cmv7.1 (Fig. 4.5.8).  
 
 
 
Fig. 4.5.8  Schematic diagram of the cloning strategy for p3xFlag-eNOS (735-940). 
 
 
 
 
 
 
 
 111To confirm the successful generation of the recombinant expression vector 
p3xFlag-eNOS(735-940), the plasmid was digested with restriction enzymes 
EcoRI and XbaI. DNA electrophoresis of the digestion reactions in agarose gels 
showed two DNA fragments corresponding to insert (615bp) and plasmid (4700bp) 
as expected (Fig. 4.5.9). 
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Fig. 4.5.9 Agarose gel electrophoresis of restriction enzyme digested p3xFlag-eNOS (735-940). 
Digestion released a fragment of DNA 615bp in size relating to amino acids 735-940 of human 
eNOS and a larger fragment of 4.7 relating to the expression plasmid p3xflagcmv7.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 1124.5.2 Analysis of the interaction between PMCA2 and recombinant Flag-tagged 
eNOS proteins 
Flag-tagged fusion proteins containing the amino acid regions 1-505, 193-733, 
401-940 and 735-940 of eNOS were used to investigate the region of eNOS 
involved in the interaction with PMCA2.  
Plasmids pFlag-eNOS(1-505), p3xFlag-eNOS(193-733) and p3xFlag-eNOS(401-
940) were co-transfected into HEK293 cells with pcDNA3-PMCA2. Protein lysates 
of transfected cells were immunoprecipitated with 5F10, anti-PMCA antibody. 
Western blot was performed on immunoprecipitated proteins using an anti-Flag 
monoclonal antibody. 
Flag-eNOS(401-940) co-precipitated with PMCA2 (Fig. 4.5.10, A, lower panel) 
whereas no precipitation was observed for Flag-PMCA2(193-733) and (1-505). 
The expression levels for each recombinant protein were the same, indicating that 
lack of interaction was not due to lack of expression (Fig. 4.5.10, A, upper panel). 
These results indicate that the region 401-940 of human eNOS contains the 
domain responsible for the interaction with PMCA2. 
To further define the region of eNOS involved in the interaction, plasmids p3xFlag-
eNOS(735-940) and p3xFlag-eNOS(1-505) were co-transfected into HEK293 cells 
with pcDNA3-PMCA2. Protein lysates of transfected cells were 
immunoprecipitated with 5F10, anti-PMCA antibody. Western blot was performed 
on immunoprecipitated proteins using an anti-Flag monoclonal antibody. 
Flag-eNOS(735-940) co-precipitated with PMCA2, whereas no precipitation was 
observed for Flag-eNOS(1-505) (Fig. 4.5.10, B, right panel). Both recombinant 
proteins were expressed at similar levels indicating that lack of interaction was not 
due to lack of expression (Fig. 4.5.10, B, left panel). 
These results demonstrate that the region 735-940 of eNOS is involved in the 
interaction with PMCA2. 
 
 
 
 
 
 
 
 113 
 
 
 
 
 
 
 
 
 
Fig. 4.5.10 PMCA2b interacts with the region 735-940 of eNOS A, HEK293 cells were co-
transfected with human PMCA2b and Flag-tagged deletion mutants of eNOS encoding amino acids 
401-940, 193-733, or 1-505. Protein lysates were immunoprecipitated with the 5F10 anti-PMCA 
monoclonal antibody and subjected to Western blot analysis with the M2 anti-Flag monoclonal 
antibody. PMCA2 interacted with F-eNOS(401-940) but F-eNOS-(193-733) or –(1-505) did not co-
precipitate PMCA2b. This indicated that the region 733-940 of eNOS is essential for the interaction 
with PMCA2b. B, HEK293 cells were co-transfected with human PMCA2b and Flag-tagged deletion 
mutants encoding amino acids 735-940 or 1-505. Western blot was performed on 
immunoprecipitated protein lysates and revealed that F-eNOS(735-940) co-precipitated with 
PMCA2b but F-eNOS(1-505) failed to co-precipitate PMCA2. In summary the region 735-940 of 
eNOS is essential for eNOS interaction with PMCA2b. A representative result from three 
independent experiments is shown. 
  
4.6 Functional analysis of the interaction between PMCA2 and eNOS in 
primary endothelial cells 
To determine the functionality of the interaction between PMCA2 and eNOS the 
levels of cGMP were measured, using a kit from Amersham, in the presence or 
absence of ectopically expressed PMCA2. cGMP levels were used as a surrogate 
marker for the production of NO from eNOS. NO produced from eNOS activates 
guanylyl cyclases to convert GTP to cGMP, therefore, the levels of cGMP are 
directly proportional to NO production. 
Plasmid pcDNA3-PMCA2 and pcDNA3-empty were transfected into HUVEC cells 
using the Amaxa method (described in section 2.1.6a(ii)). Cells were stimulated 
with the calcium Io A23187 and treated with superoxide dismutase, IBMX and L-
Arginine prior to cGMP measurement. cGMP was measured in fmol/mL according 
to the manufacturer’s instructions. 
 114Samples expressing PMCA2 had a 43% reduction in NO-dependent cGMP 
production (Fig. 4.6.1). The control using pcDNA3-empty was used as the baseline 
for cGMP production and fold induction was calculated for the experimental results 
(Fig. 4.6.1). 
These results indicate that PMCA2 inhibits eNOS NO production when 
overexpressed in endothelial cells.  
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Fig. 4.6.1 Ectopic expression of human PMCA2 negatively regulates NO production in HUVEC 
endothelial cells. HUVEC cells were transfected with 5 µg of plasmids pcDNA3-hPMCA2b or pF-
PMCA2b(462-684). A23187 ionophore (0.5 µM) was added 3 minutes before lysis to induce NO 
synthesis. NO-dependent cGMP production was calculated in relation to HUVEC cells transfected 
with 5 µg of pcDNA3 empty vector. Human PMCA2 overexpression resulted in significantly reduced 
(43%) NO-dependent cGMP production. (*) statistically significant (P≤0.05, according to an 
unparied Student’s T-test) compared to the pcDNA3 control. Mean ±S.E of six independent 
experiments are shown. 
 
 
 
 
 1154.7 Disruption of the interaction between PMCA2 and eNOS using Flag-
PMCA2(462-684) in endothelial cells 
4.7.1. Analysis of the effect of Flag-PMCA2(462-684) overexpression on the 
Interaction between PMCA2 and eNOS. 
Region 462-684 of PMCA2 encompasses the interaction domain of PMCA2 with 
eNOS. We hypothesised that by introducing a high concentration of this region in 
endothelial cells the endogenous interaction between PMCA2 and eNOS could be 
disrupted.  
To demonstrate this, endothelial cell lysates were immunoprecipitated with 5F10, 
anti-PMCA antibody. The immunoprecipitated proteins were incubated with 
various concentrations of Flag-PMCA2(462-684) recombinant protein, (purified as 
described in section 2.3.3), to determine if this could disrupt the endogenous 
interaction between PMCA2 and eNOS, Flag-empty protein was used as a control. 
Western blot analysis was performed on the final mixtures using polyclonal anti-
eNOS (Sigma). 
Addition of a high concentration of Flag-PMCA2(462-684) recombinant protein to 
the protein lysates resulted in a significant reduction of immunoprecipitated eNOS 
(Fig. 4.7.1), whereas protein lysates incubated with Flag-empty and low 
concentrations of Flag-PMCA2(462-684) demonstrated no effect on the 
immunoprecipitation of eNOS (Fig. 4.7.1). 
These results demonstrate that region 462-684 of PMCA2 is capable of disrupting 
the interaction between endogenous PMCA2 and eNOS in endothelial cells. 
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Fig. 4.7.1 The interaction between endogenous PMCA2 and eNOS in endothelial cells is disrupted 
by PMCA2 region 462-684. Endothelial cell protein extracts were immunoprecipitated with 5F10 
anti-PMCA monoclonal antibody. Immunoprecipitation reactions were incubated with 100 or 900 µl 
of elution solution containing purified F-PMCA2(462-684) adjusted to a final volume of 1 ml with 
RIPA buffer. Western blot analysis with an anti-eNOS rabbit polyclonal antibody was used to 
determine eNOS protein co-precipitation. A significant decrease in the levels of co-precipitated 
eNOS was observed when excess recombinant F-PMCA2(462-684) was included. The levels of 
co-precipitation of eNOS were not altered when control immunoprecipitations were incubated with 
identical amounts of Flag elution solution obtained after transfection of HEK293 cells with pF-
CMV7.1 empty vector. The region 462-684 of PMCA2 is capable of disrupting the interaction 
between endogenous PMCA2 and eNOS. A representative result from three independent results is 
shown. 
 
4.7.2 Functional analysis of the disruption of the interaction between PMCA2 and 
eNOS by Flag-PMCA2(462-684) in endothelial cells. 
To determine if the disruption of the interaction between PMCA2 and eNOS by 
Flag-PMCA2(462-684) had an effect on the inhibition of eNOS by PMCA2 a cGMP 
assay was performed.   
Plasmid pFlag-PMCA2(462-684) and pcDNA3-empty were transfected into 
endothelial cells using the Amaxa method. Cells were stimulated with calcium Io 
A23187 and treated with superoxide dismutase, IBMX and L-Arginine prior to 
cGMP measurement. cGMP was measured in fmol/mL according to the 
manufacturer’s instructions. 
Samples expressing Flag-PMCA2(462-684) had a significant 49% increase in NO-
dependent cGMP production, compared to the control pcDNA3 basal levels (Fig. 
 1174.7.2). The control pcDNA3-empty was used as the baseline for HUVEC cGMP 
production (Fig. 4.7.2). 
These results indicate that Flag-PMCA2(462-684) can disrupt the inhibitory effect 
of endogenous PMCA2 on eNOS resulting in an increase of total NO synthesis. 
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Fig. 4.7.2 Flag-PMCA2(462-684) can disrupt the inhibitory effect of PMCA2 on eNOS. The 
interaction between endogenous PMCA and eNOS was disrupted by overexpression of the region 
462-684 of PMCA2 and resulted in a significantly increased (49%) NO-dependent cGMP 
production. (#) statistically significant (P≤0.01, according to an unpaired student’s T-test) compared 
to the pcDNA3 control. Mean ± S.E. of six independent experiments are shown.  
 
 
 
 
 
 
 
 
 1184.8 Discussion 
It has been previously described that PMCA4 interacts with and inhibits the activity 
of the neuronal form of NOS (Schuh et al., 2001). It was the aim of this research to 
identify any isoform-specific interaction between PMCA and eNOS in endothelial 
cells and determine its functionality. 
 
This investigation has demonstrated that endogenous eNOS and PMCA2 interact 
in endothelial cells, leading to a decrease in NO production by activated 
endothelial cells. In agreement with our observations on the functional relevance 
of the interaction PMCA2/eNOS as a novel mechanism for eNOS regulation, 
inhibitory interactions between eNOS and the intracellular domains of other 
plasma membrane proteins such us: caveolin-1 (Garcia-Cardena et al., 1997), the 
bradykinin B2 receptor (Ju et al., 1998) the endothelin-1 ETB receptor (Marrero et 
al., 1999) and the angiotensin II AT1 receptor (Marrero et al., 1999) have been 
previously reported. 
 
This project also demonstrated that the interaction with eNOS maps to the region 
462-684 of PMCA2, which is located in the large intracellular catalytic domain, 
defined by trans-membrane segments 4 and 5. As described in chapter 3 an 
inhibitory interaction between the same domain of PMCA2 and the 
calcium/calmodulin-dependent phosphatase calcineurin A (Holton et al., 2007). 
The interaction of another calcium/calmodulin-dependent protein with the same 
domain of PMCA2 suggests an important role for this region in the association with 
partner proteins that are regulated by calcium. We have also located the 
interaction domain with PMCA2 to the region 735-940 of eNOS. Overexpression of 
the PMCA2 interaction domain disrupts the interaction between endogenous 
PMCA2 and eNOS in endothelial cells. 
 
4.8.1  eNOS and cancer growth 
There is substantial evidence to suggest that tumour cells need eNOS to maintain 
their growth by the production of NO and subsequent activation of oncogenic 
signalling, this has been demonstrated by Lim et al. (2008) in human pancreatic 
cancer cells where eNOS initiates and maintains tumour growth by oncogenic Ras 
signaling. 
 119The production of NO from NOS has been described to have a biphasic effect on 
the rate of apoptosis, with high levels of NO resulting in increased apoptosis and 
lower levels giving protection against apoptosis (Mortensen et al., 1999), however, 
the precise levels which induce the switch from pro-apoptosis to anti-apoptosis 
may differ depending in the cell type involved (Ridnour et al., 2008).  
Lee et al. (2001) have shown that increased NO promotes apoptosis mediated by 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-
inducing cytokine, in colorectal carcinomas. In support of this melanoma cells (Qiu 
et al., 2003) and breast cancer cells (Mortentsen et al., 1999) have also been 
shown to enter apoptosis under conditions of high NO concentration. It has 
already been described that PMCA2 is highly expressed in breast cancer cells 
(Lee et al., 2005), possibly resulting in decreased NO production by eNOS. eNOS 
seems to be the predominant isoform of NOS expressed in breast cancer cells 
(Martin et al., 1999) therefore the introduction of the small interfering peptide F-
PMCA2(462-684), may be useful in increasing NO production by eNOS and 
subsequent apoptosis. eNOS has been found to be expressed in colorectal (Yeh 
et al., 2009) and in melanoma cancers  (Tu et al., 2006). It would be interesting to 
determine the expression profile of PMCA2 in these cell types and eNOS and 
PMCA2 expression in other cancer types which are also susceptible to NO-
mediated apoptosis. 
 
4.8.2  eNOS and angiogenesis in cancer 
eNOS is the predominant isoform of NOS expressed in the endothelial cells which 
are important in the development of new blood vessels. PMCA has been reported, 
during this investigation, to be expressed in endothelial cells and the predominant 
isoform of PMCA involved in the interaction with eNOS in these cells is PMCA2.  
Angiogenesis is an important process in the progression of cancer by providing the 
growing tumour with a structured vasculature supplying nutrients and oxygen, 
essential for cell survival as well as providing an avenue for tumour metastasis. 
For this reason specific inhibitors of pathological angiogenesis are of vital 
importance in cancer therapy. Endogenous inhibitors of angiogenesis are already 
in use (Reviewed in Dass et al., 2007). The mechanism of action of these 
inhibitors is in part by inhibition of VEGF, however, this has wide-ranging side-
effects, such as hypertension, leading to coronary heart disease, stroke and heart 
 120failure (Picirillo et al., 2004) and can also be bypassed by the tumour escape 
mechanisms which involve the induction of other pro-angiogenic growth factors 
such as FGF and TGF (reviewed in Drevs 2008). eNOS is often activated by 
VEGF, FGF and TGF signalling resulting in increased NO production and 
subsequently increased blood vessel formation (Bussolati et al., 2001) and 
heightened risk of metastasis (Shang and Li. 2005) in many tumour environments 
including human gastric cancer (Wang et al., 2005), human primary astrocytoma 
cells (Pan et al., 2005) and malignant melanomas (Tu et al., 2006). Ways to 
modulate eNOS activity in endothelial cells in a specific and controlled way may 
have lesser side-effects than found in current therapies and reduce the number of 
“escape avenues” for tumour progression. The use of PMCA2 as an endogenous 
angiogenesis inhibitor via eNOS inhibition has potential, perhaps as a 
combinational therapy with VEGF signalling inhibitors, if its expression can be 
localised to the endothelial cells of blood vessels surrounding tumours.    
 
4.8.3  eNOS and diabetic retinopathy 
Diabetic retinopathy is a serious side-effect of diabetes involving increased, 
abnormal angiogenesis. The eNOS signalling pathway has been shown to be 
upregulated in retinal endothelial cells under conditions of increased glucose 
(Huang and Sheibani 2008). The expression of PMCA2 in endothelial cells has 
been described during this work as has its involvement in the inhibition of eNOS 
activity. It is therefore reasonable to hypothesise that PMCA2 overexpression in 
endothelial cells in proximity to the retina would be a beneficial therapy for diabetic 
retinopathy by reducing aberrant blood vessel growth. 
 
4.8.4  eNOS and arteriogenesis 
Activation of arteriogenesis, development of small pre-existing arterioles into larger 
vessels, could play an important role as a therapy for heart disease such as 
ischemia induced by occluded arteries. Reports suggest that increased NO can 
stimulate vessel growth in ischemic limb models (Murohara et al., 1998 and Yu et 
al., 2005). Although shear stress significantly upregulates eNOS activity the use of 
a small disrupting peptide, such as Flag-PMCA(462-684) to release eNOS from 
endogenous PMCA2 inhibition and further enhance its activity may be a useful 
therapeutic tool for arteriogenesis after ischemia.  
 1214.8.5  eNOS and cardiac hypertrophy 
eNOS is a crucial regulator of cardiovascular physiology and consequently it is 
important in pathological conditions of the cardiovascular system due to its 
production of the important mediator chemical NO. A novel role for the plasma 
membrane calcium/calmodulin ATPase pump, PMCA4, as a negative regulator of 
NO signalling has been elucidated (Schuh et al., 2001) and demonstrated to have 
physiological relevance in the heart by Oceandy et al. (2007). This project has also 
shown that PMCA2 is an important negative regulator of eNOS in endothelial cells. 
NO from endothelial cells is important in cardiovascular physiology due to its 
involvement in angiogenesis, vasodilation and regulating smooth muscle 
contraction (reviewed in Feron et al., 2006). All these functions are crucial to 
maintaining a healthy cardiovascular system. PMCA is hypothesised to play a part 
in cardiac hypertrophy, the aberrant thickening of the ventricular wall (Hammes et 
al., 1998). It was discovered that overexpression of PMCA in cardiomyocytes 
resulted in increased growth rate in a hypertrophic model. Since NO is known to 
suppress abnormal proliferation it is possible that this overexpression of PMCA 
inhibited the NO signalling pathway resulting in hypertrophy. A therapeutic tool for 
this discovery would be to disrupt the interaction between PMCA and eNOS 
increasing NO production resulting in decreased growth rate and diminished 
hypertrophy. This could be achieved by using the F-PMCA2(462-684) peptide 
created during this work, known to disrupt the inhibitory effect of PMCA2 on 
eNOS. 
 
4.8.6  eNOS and atherosclerosis 
NO from eNOS is important in modulating vascular permeability and inflammation 
which are key components in the progression of atherosclerosis (reviewed in 
Frank et al., 2003). Levels of NO in the vascular endothelium are often diminished 
(reviewed in Napoli et al., 2006) contributing to atherosclerotic plaque formation. In 
order to enhance levels of NO in the vascular endothelium it would be beneficial to 
decrease the levels of inhibitory interactions upon eNOS, such as PMCA2. By 
overexpressing the F-PMCA2(462-684) peptide the endogenous eNOS/PMCA2 
interaction could be disrupted resulting in increased NO production and reduced 
plaque formation. 
 
 1224.8.7  PMCA, eNOS and calcineurin 
An examination of the sequences corresponding to the interaction domains of 
eNOS (Chapter 4)  and calcineurin A (Buch et al., 2005) with PMCA2 did not show 
any significant homology between the two regions, suggesting that, probably, 
eNOS and calcineurin interact with two different small fragments within the region 
462-684 of PMCA2. This leads to the intriguing possibility that PMCA, eNOS and 
calcineurin might be present in endothelial cells as a ternary complex.  
Multi-site phosphorylation represents another mechanism involved in the 
regulation of eNOS enzymatic activity (Mount et al., 2007). Dephosphorylation of 
Thr
495 has been shown to promote activation of eNOS (Mount et al., 2007). 
Interestingly, Harris et al. (2001) reported that calcineurin mediates eNOS- Thr
495 
dephosphorylation (Harris et al., 2001). We have previously reported that PMCA2 
inhibits calcineurin activity (Chapter 3) (Holton et al., 2007), thus, if PMCA2, 
calcineurin and eNOS are part of a macromolecular ternary complex, PMCA-
dependent inhibition of calcineurin would result in a decrease in dephosphorylation 
of Thr
495 contributing to eNOS inhibition. Our experiments do not rule out the 
possibility that part of the increase in eNOS activity observed after ectopic 
expression of Flag-PMCA2(462-684), is due to disruption of the interaction 
PMCA/calcineurin, leading to activation of calcineurin activity and subsequent 
dephosphorylation of eNOS-Thr
495. The precise mechanism responsible for this 
increase in eNOS activity requires further investigation.  
The possibility that PMCA2, calcineurin and eNOS are forming a ternary 
macromolecular complex, introducing a new level of regulation in NO production 
by endothelial cells requires further investigation. Supporting this hypothesise 
PMCA has been reported to participate in the organisation of a macromolecular 
protein complex formed by endogenous PMCA, α-1 syntrophin and nNOS in 
cardiac cells (Williams et al., 2006). Evidence in support of this model is also given 
by a study by Yang et al., 2008 where they demonstrate that treatment of 
endothelial progenitor cells (EPC) with cyclosporine A, a known calcineurin 
inhibitor, results in increased eNOS mRNA and NO production.  
 
 
 
 
 1234.9 Conclusion 
In conclusion, this work shows an inhibitory interaction between endogenous 
PMCA2 and eNOS in human endothelial cells, and suggests PMCA2 as an 
important regulator of NO signalling in endothelial cells. Considering the relevant 
role of NO in cardiovascular physiology, apoptosis and angiogenesis, the 
implications of this interaction are far-reaching. Modulation of the interaction 
PMCA2/eNOS might, therefore, have an important significance as a potential 
therapeutic target to modulate NO in patients with cardiovascular disease, cancer 
and aberrant angiogenesis.  
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5. CHAPTER FIVE 
 
 
FUTURE WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1255.1  PMCA2 and calcineurin 
This project has confirmed that PMCA2 interacts with calcineurin in an isoform-
specific manner in breast cancer cells and that this interaction inhibits calcineurin 
activity. The importance of this discovery is clear from the number of physiological 
and pathological processes in which PMCA2 and calcineurin are involved. Further 
work into the characterisation of this interaction and its functional consequences in 
breast physiology and endothelial cell signalling are essential and ultimately very 
rewarding. 
 
To further characterise the functionality of the interaction between PMCA2 and 
calcineurin the effect of PMCA2 overexpression on the rate of apoptosis in breast 
cancer cells should be assessed. It has been hypothesised during this work that 
calcineurin inhibition by PMCA2 would result in a reduction of calcineurin-mediated 
apoptosis.  
It has been reported that paclitaxel treatment of MCF-7 breast adenocarcinoma 
cells results in FasL-mediated apoptosis of these cells. Expression of FasL in 
MCF-7 cells treated with paclitaxel is dependent on the full activation of the 
calcineurin/NFAT pathway, therefore, disruption of the interaction 
PMCA2/calcineurin by the overexpression of the region 462-684 should increase 
calcineurin activity in cancer cells and thus calcineurin-mediated apoptosis. 
Further work in Dr Armesilla’s laboratory will focus on overexpressing the region 
462-684 of PMCA2 in breast cancer cells and evaluating its effects on paclitaxel-
induced apoptosis and FasL expression. 
 
It would also be interesting to determine if the interaction between PMCA2 and 
calcineurin occurs in other cancer cells lines. Elucidating the PMCA2 expression 
profile in cancer cells would be beneficial in developing a therapy to exploit the 
apoptotic pathway involved in the PMCA2-calcineurin interaction. By creating a 
cell penetrating peptide that encodes the interaction domain of PMCA2 with 
calcineurin, its inhibition by PMCA2 could be released resulting in heightened 
calcineurin activity and subsequent apoptosis. Cell targeting to cancer cells could 
be achieved by creating a peptide that can only function in the presence of a 
cancer specific marker, such as reduced p53. 
 126Another interesting avenue of research would be to look at overexpressing 
PMCA2 in systems where a lack of PMCA2 results in a pathological phenotype, 
such as in inner ear cells. Inner ear cells express high levels of PMCA2, however, 
when this level of PMCA2 is reduced or knocked down, there is a susceptibility to 
noise-induced hearing loss. By increasing the levels of PMCA2 this should result 
in less apoptosis in these cells and possibly the healthy development of the 
calcium rich otoconia, essential for balance. This could be achieved In Vivo by 
gene therapy at an early stage of development. Localised treatment of inner ear 
cells with a plasmid containing the pmca2 gene under the control of a mammalian 
promoter using an efficient gene delivery system, such as recombinant lentivirus 
would allow for the expression of PMCA2 and possibly a reduction in noise 
induced hearing loss. 
 
5.2  PMCA2 and eNOS 
During this project the interaction between PMCA2 and eNOS has been identified 
and this interaction has been shown to reduce NO production in endothelial cells. 
The effects of PMCA and eNOS in physiological and pathological conditions are 
great, therefore this discovery has implications in the development of treatments 
for diseases where NO production is abnormal. Further characterisation of this 
interaction and its effects are of vital importance. 
 
To further characterise the interaction between PMCA2 and eNOS, the exact 
mechanism used by PMCA2 to inhibit the activity of eNOS should be determined. 
It is thought that PMCA inhibits the activity of calcium/calmodulin-dependent 
enzymes by sequestering these proteins to a low calcium micro-domain generated 
by the calcium extrusion properties of PMCAs. 
Currently being investigated in Dr Armesilla’s lab is the possibility that PMCA2 
inhibits the dephosphorylation of Thr
495, the negative regulatory serine of eNOS. 
Interestingly it has been reported that the dephosphorylation of eNOS Thr
495 can 
be carried out by calcineurin. PMCA2 could be overexpressed in endothelial cells 
and using an antibody specific for eNOS phosphorylation site Thr
495 the effect of 
this could be demonstrated. The work in this thesis (Chapter 3) has shown that 
PMCA2 is a negative regulator of calcineurin activity and, therefore, PMCA2-
 127mediated inhibition of calcineurin might lead to a lack of eNOS Thr
495 
dephosphorylation and result in inhibition of eNOS activity.  
 
To confirm that the interaction between PMCA2 and eNOS is relevant in 
physiological terms the effect of overexpressing PMCA2 in an angiogenesis model 
could be performed. This could be achieved by growing endothelial cells on a 
collagen or fibrin matrix such as matrigel to assess the number of vessel-like tubes 
formed when PMCA2 is overexpressed. Hypothetically the number of tubes 
formed should reduce when PMCA2 is overexpressed as PMCA2 is inhibiting the 
activity of eNOS and NO production resulting in a lack of proangiogenic signalling. 
It would also be interesting to determine whether expression of the PMCA2 
interaction domain protein could enhance tube formation by releasing eNOS from 
endogenous PMCA2 inhibition. This overexpression would also release calcineurin 
from the inhibitory effects of PMCA2 possibly resulting in increased NFAT-
dependent gene activation and angiogenesis promotion. 
 
It would also be interesting to investigate the PMCA2-eNOS interaction in other 
endothelial cells as there is evidence that there are significant differences between 
endothelial cells derived from large or small vessels and different organ sites 
(reviewed in Aubach et al., 2003). In particular microvascular endothelial cells are 
particularly relevant to angiogenesis in pathological diseases such as vascular 
dysfunction. This further characterisation would help in identifying the best 
treatment for angiogenic related diseases such as cancer metastasis. 
 
 
5.3  PMCA2, eNOS and calcineurin 
An interesting question arising from this work is that PMCA2, eNOS and 
calcineurin exist as a ternary complex in cells and that PMCA, as well as 
regulating their activity is involved in localising both proteins to the same vicinity as 
each other. Determining if this is the case would be an important insight into the 
mechanism of the regulation by PMCA2 of signal transduction pathways 
 
 
 128Initially it would be important to determine if the low calcium microenvironment 
causes the decrease in calcineurin and eNOS activity or whether the interaction 
with PMCA2 results in direct inhibition of activity by another process. By creating a 
functionally deficient PMCA2 mutant where the calcium extrusion activity of 
PMCA2 is reduced without altering the structure of the protein the inhibitory effect 
of PMCA2 on calcineurin and eNOS could be assessed. 
 
Future work involves defining whether PMCA2, eNOS and calcineurin exist in a 
ternary complex and how their interaction with PMCA2 results in their inhibition. 
Hypothetically the activation of eNOS depends on the dephosphorylation of the 
negative regulatory threonine residues and phosphorylation of the positive 
regulatory serine residues. This dephosphorylation of the threonine residue has 
been shown to involve calcineurin (Harris et al., 2001) implicating that PMCA2 
may dually inhibit the activity of eNOS by tethering eNOS to a low calcium 
microenvironment and inhibiting the activity of calcineurin. The development of a 
small cell penetrating peptide encompassing the region of PMCA2 involved in the 
interaction between PMCA2 and calcineurin and eNOS may cause the disruption 
of the ternary complex and release calcineurin and eNOS from the inhibition of the 
low calcium microenvironment and also allow eNOS activation by calcineurin. This 
would be a useful therapy if it could be cell specific for endothelial cells in diseases 
where NO levels are low. Releasing eNOS from endogenous inhibition may 
increase NO production. This increased NO would be important for the activation 
of angiogenic pathways that are often dysfunctional in diseases such as 
atherosclerosis. 
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Fig. 5.3.1 Hypothetical PMCA2, calcineurin, eNOS ternary complex formed in endothelial cells and 
disruption of this complex by a cell penetrating peptide encompassing the interaction region of 
PMCA2 as a therapy for disease involving dysfunctional endothelial cells caused by low NO levels. 
 
Also co-localisation experiments using confocal imagery could be performed to 
visually demonstrate that PMCA, eNOS and calcineurin exist as a ternary complex 
by providing an overview of their localization within endothelial cells. This could be 
performed in endothelial cells as each protein is endogenously expressed in these 
cells, using antibodies specific for each protein that are conjugated with different 
fluorescent dyes. Another method to demonstrate the hypothesis that calcineurin 
and eNOS interact would be to perform immunoprecipitation with anti-calcineurin 
and Western blot with anti-eNOS analysis. 
 
 
 
 
 
 
 
 1305.4 Conclusion 
The potential avenues for this research are vast with the possible involvement of 
PMCA in calcineurin-mediated apoptosis and control of NO production by eNOS. 
Since PMCA is involved in these important pathways is essential to establish its 
involvement in other pathways and the degree to which PMCA actually regulates 
them. This information would be essential for the production of therapeutic drugs 
and simply defining signalling pathways involved in these processes for future 
reference. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 131CONCLUDING REMARKS 
 
This thesis has clearly demonstrated that PMCA is a novel regulator of 
calcium/calmodulin-dependent signal transduction pathways in mammalian 
cells. This work has shown that PMCA interacts with calcium/calmodulin-
dependent proteins in an isoform-specific manner. PMCA isoform 2 region 462-
684 of the large intracellular loop was found to interact with calcineurin (region 
undefined) and eNOS at region 735-940. The calcineurin-PMCA2 interaction 
was described in; mammalian cells HEK293, breast adenocarcionoma cells 
MCF7 and endothelial cells HUVEC. The eNOS-PMCA2 interaction was 
described in mammalian cells HEK293 and endothelial cells HUVEC. PMCA2 
interacts with both proteins resulting in the significant inhibiton of their 
subsequent signalling pathways. The overexpression of F-PMCA2(462-684) 
resulted in the disruption of the endogenous interaction between PMCA2 and 
eNOS in endothelial cells HUVEC. These results demonstrate the importance 
of PMCA2 in the regulation of calcium/calmodulin-dependent signal 
transduction pathways in breast and endothelial cells and represent a novel 
and potential therapeutic avenue to pursue in the treatment of many diseases. 
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 133A1.  Primary antibody specificity 
To demonstrate the specificity of the primary antibodies used throughout this work, 
a full length picture of the western blots for each PMCA isoform and eNOS are 
included.  
 
 
PMCA2  PMCA1  PMCA4 
148kDa -  
78kDa -  
64kDa -  
148kDa -  
78kDa -  
64kDa -  
148kDa -
78kDa -
64kDa -
WB: α-PMCA4 WB: α-PMCA1 WB:  α-PMCA2
C)  A) B) 
 
Fig. A1.1  Full length pictures of whole HUVEC protein lysates on Western blots probed with 
PMCA antibodies to demonstrate the specificity of the primary antibodies. Western blots of proteins 
immunoprecipitated with 5F10 (Abcam) were probed with antibodies specific for PMCA1, -2, or -4 
(Swant). A) PMCA1 (WB: α-PMCA1), B) PMCA2 (WB: α-PMCA2) and C) PMCA4 (WB: α-PMCA4). 
Secondary antibody α-Rabbit-hrp (Sigma). 
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Fig. A1.2  Full length picture of whole HUVEC protein lysates on a Western blot probed with α-
eNOS antibody to demonstrate the specificity of the primary antibody. Western blot of eNOS was 
probed with an antibody specific for eNOS (Zymed) (WB: α-eNOS). Secondary antibody α-Mouse-
hrp (Sigma). 
 
 
 135A2. Materials 
 
Amersham 
GE Healthcare UK Ltd, 
Amersham Place, 
Little Chalfont, 
Buckinghamshire.  
HP7 9NA. 
 
cGMP enzymeimmunoassay biotrak 
(EIA) system 
 
 
ATCC 
LGC Standards,  
Queens Road, 
Teddington,  
Middlesex,  
TW11 0LY. 
 
HEK293 
MCF-7 
 
Clontech 
The Dandy Building, 
Edmund Halley Road, 
Oxford Science Park, 
Oxford. 
Oxen  
pNFAT-TA-Luc 
 
 
 
 
Geneflow 
Geneflow Ltd,  
Fradley Business Centre, 
Wood End Lane,  
Fradley , 
Staffordshire.   
WS13 8NF. 
 
Running buffer 
Transfer buffer 
EZ chemiluminescence kit 
 
 
Invitrogen Ltd, 
3 Fountain Drive, 
Inchinnan Business Park, 
Paisley, 
UK. 
PA4 9RF. 
 
Lipofectamine 
Opti-mem 
Electrophoresis grade agarose  
TAE buffer 
Ethidium Bromide 
Loading buffer (AGE) 
DNA ladder (1kB) 
Agar powder 
LB powder 
Seeblue plus2 protein marker 
Loading buffer (PAGE) 
pcDNA3 
 
 
  136Kodak, 
Kodak Limited, 
Hemel One, 
Boundary Way, 
Hemel Hempstead, 
Herts.  
HP2 7YU. 
 
Autoradiographic film 
 
 
Lonza 
Lonza Wokingham Ltd, 
1Ashville way, 
Wokingham, 
Berkshire. 
RG412PL. 
 
EGM-2 
HUVEC 
Nucleofector solution 
 
 
Marvel 
Premier foods, 
Central technical, 
The Lord Rank centre, 
Lincoln road, 
High Wycombe. 
HP12 3QS. 
 
Milk powder 
 
Millipore 
Millipore (UK) Ltd, 
3-5 The Courtyards, 
Hatters Lane, 
Watford,  
Herts.  
WD18 8YH. 
 
Nitrocellulose membrane 
 
 
National Diagnostics 
AGTC Bioproducts t/a National 
Diagnostics UK, 
Itilngs lane, 
Hessle. 
HU139 LX. 
 
Bis-acrylamide 
 
 
Pierce 
Thermo Fisher Scientific, 
p/a Perbio Science, 
Unit 9,  
Atley Way, 
North Nelson Industrial Estate, 
Cramlington,  
Northumberland.  
NE231WA. 
 
BCA protein assay kit 
 
  137Promega UK Ltd, 
Delta House, 
Southampton Science Park, 
Southampton, 
Hampshire. 
SO16 7NS. 
 
Restriction enzymes and buffers 
PCR gel clean up wizard kit 
Alkaline phosphatase 
Alkaline phosphatase buffer 
Ligase buffer 
JM109 E.Coli 
Bacteriophage T4 DNA ligase 
Luciferase lysis reagent 
Luciferase substrate 
 
 
QIAGEN, 
QIAGEN HOUSE,  
Fleming Way, 
Crawley,  
West Sussex,  
RH10 9NQ. 
 
QIAGEN maxiprep kit 
QIAGEN miniprep kit 
 
 
 
 
 
Roche Diagnostics Ltd, 
Charles Avenue, 
Burgess Hill, 
RH15 9RY.  
 
High fidelity PCR master mix 
Agarose A beads 
 
Sigma-Aldrich Company Ltd. 
The Old Brickyard, 
New Road, 
Gillingham, 
Dorset. 
SP8 4XT. 
 
A23487 calcium ionophore 
Ampicillin powder 
Aprotinin 
APS powder 
Butanol 
DMEM 
DMSO 
Ethanol 
α-Flag
®-M2 affinity gel agarose beads 
FBS 
Flag peptide 
Glycine 
HEPES buffer 
Hydrochloric acid 
IBMX 
IGEPAL 
Isopropanol 
L-Glutamine 
  138KCl powder  VHBio, 
L-Arginine powder  Unit 11B Station Approach, Team 
Valley Trading Estate, 
Gateshead. 
LB powder 
Leupeptin Hemisulphate powder 
Methanol  NE11 0ZF. 
NaAc   
Primers NaCl  
NEM 
P3xFlagcmv7.1 
pFlag5b 
PBS 
Penicillin/streptomycin  
Pepstatin A 
PMA 
PMSF 
Recombinant calcineurin 
Recombinant eNOS 
RPMI  
SDS 
Sodium Deoxycholate 
Superoxide dismutase 
TE buffer 
TEMED 
Tris base 
Trypsin-EDTA 
TWEEN20 
 
 
 
 
 
 
 
 
  139A3. Solutions 
 
Freezing solution   
FBS (90%) 
DMSO (10%) 
 
   
Luria broth  
dH2O 
LB powder (25g/L) 
+/- Ampicillin (100µg/ml)  
 
 
LB/Agar 
dH2O 
LB powder (25g/L) 
Agar powder (15g/L) 
Ampicillin (100µg/mL)  
 
 
Resolving gel  
6% gel  
dH2O 
4x 1.5M Tris buffer pH 8.8 (28.8%)  
10% of APS (0.71%)  
TEMED (0.43%) 
Bis-acrylamide (20%) 
 
 
12% gel  
dH2O 
4x 1.5M Tris buffer pH 8.8 (28.8%)  
10% of APS (0.71%)  
TEMED (0.43%) 
Bis-acrylamide (40%) 
 
 
RIPA buffer  
dH2O 
PBS (1%) 
Igepal (1%) 
Sodium Deoxycholate (0.5%)  
SDS (0.1%) 
20µM PMSF (0.05%) 
Pepstatin A (500ng/mL) 
Leupeptin (500ng/mL)  
Aprotinin (1μg/mL) 
 
 
Running buffer  
Tris base (0.25M) 
Glycine (1.92M) 
SDS (1%) 
 
 
 
 
 
 
 
  140Stacking gel    
dH2O 
Bis-acrylamide (14%) 
 4x 1.5M Tris buffer pH 6.8 (25%)  
10% APS (0.1%) 
TEMED (0.06%) 
 
 
TBS 
dH2O 
NaCl (10g/L) 
Tris base (3.75g/L) 
KCl (0.25g/L) 
 
 
TBS-T 
dH2O 
NaCl (10g/L) 
Tris base (3.75g/L) 
KCl (0.25g/L) 
 
 
Transfer buffer  
Tris base (0.2M) 
Glycine (1.5M) 
Methanol (20%) 
 
 
Tris buffer  
dH2O 
Tris base (121.14g/mol) 
1M hydrochloric acid (HCl) 
TWEEN20 (0.1%) 
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